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Abstract 
Cancer has become one of the dominant diseases worldwide, especially in western 
countries, and radiation therapy is one of the primary treatment options for 50% of all 
patients diagnosed. Radiation therapy involves the radiation delivery and planning based 
on radiobiological models derived primarily from clinical trials. Since 2015 
improvements in information technologies and data storage allowed new models to be 
created using the large volumes of treatment data already available and correlate the 
actually delivered treatment with outcomes. The goals of this thesis are to 1) construct 
models of patient outcomes after receiving radiation therapy using available treatment 
and patient parameters and 2) provide a method to determine real accumulated radiation 
dose including the impact of registration uncertainties.  
In Chapter 2, a model was developed predicting overall survival for patients with 
hepatocellular carcinoma or liver metastasis receiving radiation therapy. These models 
show which patients benefit from curative radiation therapy based on liver function, and 
the survival benefit of increased radiation dose on survival. 
In Chapter 3, a method was developed to routinely evaluate deformable image 
registration (DIR) with computer-generated landmark pairs using the scale-invariant 
feature transform. The method presented in this chapter created landmark sets for 
comparing lung 4DCT images and provided the same evaluation of DIR as manual 
landmark sets.  
In Chapter 4, an investigation was performed on the impact of DIR error on dose 
accumulation using landmarked 4DCT images as the ground truth. The study 
demonstrated the relationship between dose gradient, DIR error and dose accumulation 
error, and presented a method to determine error bars on the dose accumulation process. 
In Chapter 5, a method was presented to determine quantitatively when to update a 
treatment plan during the course of a multi-fraction radiation treatment of head and neck 
cancer. This method investigated the ability to use only the planned dose with deformable 
image registration to predict dose changes caused by anatomical deformations. 
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This thesis presents the fundamental elements of a decision support system including 
patient pre-treatment parameters and the actual delivered dose using DIR while 
considering registration uncertainties. 
Keywords 
Radiation therapy, image-guided radiation therapy, adaptive radiation therapy, decision 
support, deformable image registration, registration error 
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Chapter 1 
 
1 Introduction 
1.1 Overview 
Compared to most other diseases cancer presents a unique problem of unregulated cell 
growth, resulting from a wide range of cell mutations. These mutations create many 
different cancer types and pathologies each responding differently to treatment. Radiation 
therapy has been used since the early 1940s to provide effective treatment for many 
cancers and is currently one of the primary treatment options for cancer. Through 
different delivery methods and geometric targeting high levels of radiation can be 
delivered to cancer cells, while trying to spare surrounding healthy tissue. The challenge 
is to ensure that the necessary amount of radiation is delivered to a cancerous tumour to 
treat a patient’s disease.  
Unlike other treatment modalities, the intended amount of radiation to specific organs or 
regions can be visualized from a 3D computerized calculation (treatment plan) and be 
used to optimize disease control and limit toxicity. Radiation therapy has progressed over 
the last two decades from basic target coverage to “precision” coverage for the benefit of 
improved tumour control and reduced normal tissue damage. Unfortunately with 
precision coverage the static treatment plan (created on the patient’s pre-treatment 
anatomy) becomes less accurate as treatment progresses and the patient’s anatomy 
changes requiring new tools to characterize changes in accumulated dose during 
fractionated treatment. Image guidance was introduced to limit positioning errors and 
monitor for anatomy changes but it could not effectively compensate for anatomical 
deformations because reducing position errors is insufficient for optimized dose 
distributions. Even if the plan can be adapted when significant anatomical changes are 
noticed, it is currently difficult to determine the accumulated dose on a per voxel basis 
and the correlation with outcomes.  
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Deformable image registration (DIR) is a graphics tool that maps every point in a 
reference volume to the corresponding point in another image volume. With DIR and 
image guidance the dose received in every fraction can be mapped back to the original 
planning volume determining the cumulative delivered dose. However, DIR currently 
contains inherent uncertainty introducing quandary to the record of delivered dose. 
Currently, in radiation therapy, there is lack of information on the actual delivered dose 
due to limitations in image registration accuracy preventing effective correlation with 
patient outcomes. Historically, treatment outcomes were correlated only with patient’s 
planned dose distribution calculated prior to the start of treatment. The inclusion of 
detailed information about planned and actually delivered dose would improve the 
predictive power of treatment outcomes and optimize/personalize the treatment process.  
Ideally with an accurate record of the distribution of the received dose paired with 
outcomes and pre-treatment parameters improved personalized medicine can be realized. 
The following sections will introduce cancer, adaptive radiation therapy and deformable 
image registration to provide context for later chapters. 
1.2 Cancer 
Since the beginning of human history, our mortality has been tested from predators, 
environmental disasters, war and disease. Through cooperation and innovation, we have 
thrived in our environment and extended the average human lifespan from 30 years in the 
1800s to 67 years in the year 2000 [1]. This modern longevity can be attributed to better 
nutrition and modern medicine. Traditionally medicine sought to cure diseases from 
foreign sources including bacterial infections and viruses or to repair physical damage or 
birth defects. As many life-threatening diseases and conditions were eradicated and with 
increased life expectancy, cancer became much more prevalent especially in developed 
nations. As a fundamentally different type of disease, cancer required an entirely different 
approach. 
Cancer is not directly caused by any foreign organism or event but occurs when there is a 
significant mutation in a cell’s DNA, making cancer cells grow uncontrollably without 
normal growth regulation. The primary symptoms of a cancer cell are rapid and 
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uncontrolled growth and loss of the cell’s original function. The lethality of cancer is 
caused by the tumour’s necessity for oxygen, nutrients and space, ultimately starving 
surrounding healthy tissue as it spreads and grows. Treatment of cancer is difficult since 
it has few differences from healthy cells, unlike bacteria, and the immune system can no 
longer effectively combat it. Unlike other diseases the mutations at the root of cancer are 
a fundamental part of cellular evolution, making cancer inescapable. 
Throughout the developed world cancer is the leading cause of death, making its 
treatment and management paramount. Studies have shown specifically in Canada 1 in 2 
people will get cancer in their lifetime [2]. With such a large burden, the management of 
cancer has become a major component of healthcare costing 4.4 billion dollars in 2008 in 
both direct health care costs and lost productivity [2]. There are currently three main 
treatment modalities for cancer management; i) surgery, ii) systemic therapy and iii) 
radiation therapy. Surgery is the desired option, physically removing the malignancy but 
only applies to removable tumours and patients healthy enough to endure the procedure 
and recovery. Systemic therapies use drugs to treat cancer systemically but can create 
significant toxicities since the effects are typically poorly targeted. Radiation therapy is a 
non-surgically invasive targeted therapy, capable of treating a majority of patients, 
producing limited toxicity and easily combined with other therapies. The complexity of 
cancer diagnosis and treatment (with multiple modalities) requires accurate modelling to 
determine the optimal treatment technique. Currently, making a decision for treatment is 
challenging, because outcome prediction is made based on averaged data, while patient’s 
anatomy or disease may vary significantly. For modelling to be effective, a complete 
account of all treatment parameters is required.  
1.3 Radiation therapy 
Radiation therapy employs ionizing radiation to treat cancer, with the goal to deliver 
sufficient levels of radiation dose to a tumour while sparing surrounding healthy tissue. 
Quantitatively, the required dose to kill cancerous cells is given by tumour control 
probability (TCP) models [3-5]. Tolerance doses for organs at risk (OAR) are obtained 
from normal tissue complication probability (NTCP) models [6-7]. Recently the 
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QUANTEC publications [8] provided updated recommendations for limiting dose/volume 
parameters for OARs. 
Radiation can be delivered externally (external beam radiation therapy) or from implanted 
radiation sources (brachytherapy). The primary mechanism of radiation therapy is to 
fatally damage cancer cells by breaking their DNA leading to cell death. Every radiation 
therapy treatment plan begins with a CT simulation representing the patient’s anatomy in 
three dimensions and depicting (and contrasting) the electron density of different tissues 
required for dose calculation. An example of a CT simulation is presented in Figure 1-1 
with the axial, sagittal and coronal cross-sections of a CT volume with the gray scaling 
illustrating the different electron densities. Contours are produced to identify individual 
tissue types, OAR and target the tumour.  
 
Figure 1-1: CT image study of head and neck region a) axial b) sagittal c) coronal. 
The radiation treatment plan is optimized for the patient’s contoured CT simulation to 
select the best combination of radiation beams produced at different angles overlapping 
on the target region demonstrated in Figure 1-2. 
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Figure 1-2: Image of overlapping intensity modulated radiation therapy (IMRT) fields generated by 
specific multi-leaf collimator (MLC) configurations. Colour map represents the dose distribution. 
Image from http://www.ofunachuohp.net/rt/technique.html. 
A radiation treatment plan is generated as the result of applying targeted beams to a 
tumour while limiting the dose to organs at risk. Historically treatments were delivered 
using large rectangular fields with wedged beams or lead blocks which could cause 
significant toxicities from less conformal dose distributions. With higher precision 
delivery tools developed in the mid-nineties such as multi-leaf collimators (MLC) and 
Intensity-modulated radiation therapy (IMRT) toxicity was reduced compared to earlier 
treatment techniques [9]. In modern radiotherapy practice, there are many degrees of 
freedom, including beam angles, energy and modulation utilizing an MLC that defines the 
treatment plan. An MLC is a series of tungsten segments that shape the radiation field 
during treatment shown for each beam in Figure 1-2. Optimization of these parameters to 
satisfy the prescribed dose constraints creates highly conformal dose distributions, 
displayed in the centre of Figure 1-2. With further improvements and the combination of 
arcing, varied dose rate and beam modulation, volumetric arc therapy (VMAT) was 
developed in 2010 improving plan quality further [10-13] with reduced treatment times. 
As technology developed, the ability to deliver radiation with pinpoint accuracy has 
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become possible, but the difficulty lies with adapting to anatomical changes during 
treatment while maintaining the same precision and accuracy. 
1.4 Patient outcomes 
Radiation delivery has improved significantly with the introduction of new techniques 
including IMRT, VMAT, and proton therapy, but though technically superior they have 
shown limited improvements in patient outcomes especially when related to their cost. 
Health care costs are increasing unsustainably in the developed world with the USA 
spending 17.2% of their GDP on healthcare in 2017 as shown from the OECA health 
statistics [14]. Much of the increase in spending will come from private insurers 
increasing premiums, funding cuts to other programs and increased taxation. The concept 
of value in healthcare has been largely avoided, especially within a private health care 
system like in the US. The value approach has attracted considerable attention in many 
countries employing a single payer system (i.e. Canada) leading to a  near 50% reduction 
in health care spending per capita compared to the US [14] without compromising health 
care. The concept of value is simple, benefit (i.e. patient survival or quality of life) 
divided by cost but in practice, it is more difficult to define. As costs continue to soar 
with the development of new drugs, imaging and technology the value we are receiving is 
decreasing and this rate of development may challenge the benefits of randomized clinical 
trials. To justify higher cost options healthcare service providers must provide evidence 
of extended quantity and quality of life obtained through impactful outcome research. 
Outcome research is an integral part of the value discussion helping to define the real-
world benefit from new treatments and technologies. Only with a clear definition of both 
the benefits and the opportunity costs of medical treatments can healthcare become 
sustainable. This issue of value-centred care has been discussed in radiation oncology 
[15-17] where patient outcomes and cost can vary greatly.  
The difficulty for radiation oncology is how to effectively measure benefits and cost 
while accounting for both patient-specific parameters and radiation delivery options. As 
radiation treatments progress there are biological and anatomical changes that impact how 
the radiation is received making it difficult to compare treatments based only on their 
initial plans. For example, recent studies predicting patient outcomes avoid including 
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specifics on how the treatment was delivered [18, 19] and consider using more advanced 
imaging parameters like Radiomics [20]. Even in studies trying to model radiation effects 
on TCP and NTCP only the prescribed dose is considered [21, 22]. For a true assessment 
of value, a better understanding of what treatment was delivered is necessary otherwise 
any real effect could be misinterpreted.  
In chapter 2 we have presented a determination of overall survival for liver cancer 
patients and include treatment parameters, and demonstrate the poor prognostic value of 
using only the prescribed dose. A multivariable analysis presented the possibility of the 
advantage of including additional parameters namely a uniform low dose to surrounding 
tissue [23]. Previous predictive liver cancer models had not included the effect of 
radiation dose [24, 25] or did not include all other pertinent liver function and disease 
parameters [26]. 
The inclusion of the actual delivered dose that accounts for daily anatomy changes 
enhances the predictive power. Decision making based on complex data including pre-
treatment patient characteristics, planning parameters, delivered dose is technically 
feasible in the era of integrated electronic records and treatment planning systems as 
demonstrated in our previous work on the design of a clinical database system [27]. With 
the complete picture of treatment delivery more clinical trials and machine learning can 
be performed to obtain a better understanding of the value added by new treatment 
techniques. 
1.5 Image guided radiation therapy 
Typical radiation therapy treatments are delivered over multiple fractions ranging from 
three fractions delivered over the course of a week, to 30 or more. As treatment 
progresses it is difficult to determine how well the delivered dose matches the prescribed 
dose without additional imaging and tracking data. Historically as radiation treatment 
plans became more advanced daily imaging was introduced to ensure patient alignment to 
the planning position before each treatment and check for significant anatomical changes. 
This process is called Image-guided radiation therapy (IGRT) and involves patient setup 
using external markers (tattoos and immobilization devices) followed by imaging 
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performed with onboard megavoltage (MV) or kilovoltage (kV) imaging systems. Once 
images have been obtained couch shifts are applied to ensure the patient is in the correct 
(planned) position relative to the treatment field. Current forms of image guidance 
include 2D kV, MV CT (used on Tomotherapy), CT on rails and cone beam CT (CBCT). 
A radiation therapy treatment plan is optimized to deliver a radiation dose to the gross 
tumour volume (GTV) with margins added to incorporate potential microscopic disease 
spread creating a clinical target volume (CTV). Furthermore, to account for set up and 
radiation delivery errors an additional margin is introduced creating the planning target 
volume (PTV). These margins were defined by the international commission on radiation 
units and measurements (ICRU) reports 50 [28], 62 [29] and 83 [30]. With increased 
margins delivering higher levels of radiation to the PTV became challenging because the 
PTV can overlap or be in close proximity to sensitive organs. Image-guided radiation 
therapy improves the accuracy of treatment delivery with smaller PTV margins and 
allows for target conformal treatments with higher doses.  
Clinically IGRT has paved the way for more aggressive treatment options providing 
better outcomes for patients without the risk of toxicities.  A study by Zelefsky et al. 
demonstrated reduced urinary toxicity, and improved survival for high-risk prostate 
cancer patients using IGRT, compared to standard IMRT [31]. There have been recent 
studies describing the improvements brought by IGRT for prostate [32-34], lung [35], 
brain [36] and head and neck [37]. As the cost of implementing IGRT is large it is 
important to optimize the IGRT process by making it patient specific and determine the 
sub-group of patients and disease sites where IGRT has a significant impact on clinical 
outcomes. IGRT also provides accurate records of the patient’s anatomy throughout 
treatment. 
1.6 Adaptive radiation therapy 
Radiotherapy is planned on a patient’s static anatomy provided by CT simulation before 
the start of treatment. As the treatment fractions are delivered the patient’s anatomy often 
changes and affects how the dose is deposited. These dose changes to the target and 
surrounding healthy tissue influence disease control and/or increase the risk of 
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complications. To counteract anatomical changes the treatment plan can be modified via 
adaptive radiation therapy to minimize deviation from the original plan. Such 
modification is only needed for sites where anatomical changes are important based on 
the impact on the cumulative dose distribution. 
Adaptive radiation therapy is the modification of a plan during a multi-fraction radiation 
treatment in response to changes in the patient’s anatomy and disease. These changes can 
include weight loss, body functions (bladder/rectum filling/emptying), breathing, setup 
errors and tumour progression or shrinkage. Multiple studies have shown significant 
benefits in survival and reduced toxicity by adapting treatments [38, 39]. Unfortunately, 
there is currently no standard adaptation strategy with different centres and studies having 
different approaches. Nijkamp et al. adapted treatment after fraction 6 out of 39, using the 
average PTV measured from the previous 6 treatments [40]. Whereas earlier studies 
would perform a new CT simulation after a specific amount of dose has been delivered to 
a tumour [41, 42]. Most institutions use image guidance to monitor the patient’s anatomy, 
using different image matching techniques and action levels. When large changes are 
observed the treating physician can require an adaptation to their treatment and he/she is 
responsible for the final decision. Such a decision is typically based on observations of 
anatomy changes only, while the clinical assessment should include changes in the dose 
distribution. Currently, this dose-effect evaluation is achieved only by repeated full CT-
simulation with contouring and dose calculation. In chapter 5 a method is presented to 
provide an automatic daily evaluation of the necessity of plan adaptation for head and 
neck cancer without additional imaging and dose calculations. Without a standard 
approach, comparison of treatment outcomes with respect to radiation treatment is 
difficult since they will be adapted at different points. 
Any radiation treatment plan is dependent on the imaging acquired for diagnostic or 
planning to provide a complete picture of a patient’s anatomy and disease. All modern 
imaging modalities produce a 3D volume with voxel values representing electron density, 
cellular structure or cellular processes. Radiation therapy is targeted to voxels suspected 
of cancer and avoids voxels of sensitive structures typically highlighted by contours. 
Unfortunately, contoured regions are only present on the planning CT simulation and can 
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change significantly throughout treatment. No longer can the planned dose to individual 
voxels or structures be used to correlate with outcomes without accounting for anatomy 
change and plan adaptation. Currently, the only effective method to track dose changes 
from anatomy change and to perform plan adaptation is with deformable image 
registration. 
1.7 Deformable image registration 
1.7.1 Background 
Image registration is the process of pairing two image volumes together that are both 
derived from the same object. There are multiple objectives for employing image 
registration, for example, registering images of an object viewed from different points, 
different image modalities or after experiencing deformation. Each of these scenarios 
occurs frequently for medical imaging using CT, magnetic resonance imaging (MRI) and 
positron emission tomography (PET). Independent of the application, the goal of image 
registration is to map every pixel on every slice (or voxel in 3D) from one image space to 
another. 
In radiotherapy, image registration is primarily used to delineate cancerous regions 
(GTV) and sensitive structures from diagnostic images (MRI or PET) and propagate the 
contours to the planning CT study. MRI is commonly used for superior soft tissue 
contrast compared to CT for target delineation for many treatment sites including prostate 
[43], cervical [44], brain [45], and head and neck [46]. But MRI does not contain the 
electron density values required for radiotherapy planning. Image registration can 
facilitate the transfer of diagnostic information from MRI to CT to facilitate dose 
calculation and treatment planning. An example of improved target delineation is 
presented in Figure 1-3a for the bladder, tumour and rectum in the female pelvis [44]. 
Another important accompanying imaging modality is PET, which can locate and stage 
disease using its metabolic activity detected by specifically labelled radioisotopes, 
primarily fluoride 18. PET imaging has greatly improved target delineations [47] 
especially for thoracic cancers [48, 49]. When a PET image is registered to a planning 
CT, a “fused” image is generated indicating areas of glucose uptake or cancer 
aggressiveness as a colour map shown in Figure 1-3b. 
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Figure 1-3: a) checkerboard overlap of MRI and CT of female Pelvis [44] B) CT image and CT image 
with PET colour map showing metabolic activity and highlighting lesion [50]. Permission for both 
figures is presented in Appendix A.1 & A.2. 
As treatment methods improved, IGRT and adaptive radiation therapy became common, 
traditional rigid registration was no longer always suitable because patient’s anatomy 
would deform non-linearly throughout treatment. Now multiple image studies are 
collected at different time points which are anatomically different. To solve this problem 
deformable image registration (DIR) was introduced [51] to map every point between 
image spaces non-linearly, producing a deformation vector field (DVF), an example 
illustrated in Figure 1-4. A DVF can deform contours from the planning image to daily 
images and after calculating the dose distribution compare and accumulate the dose from 
each fraction. The final goal is to effectively track and accumulate the radiation dose 
being delivered from each fraction to correlate real delivered dose with patient outcomes. 
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Figure 1-4: Example of a deformation vector field, shown in the interface from the Varian Velocity 
software suite. 
1.7.2 DIR fundamentals 
The results of a DIR for an individual point can be interpreted as the vector between the 
point from the original image space (x,y,z)  to the new image space (x’,y’,z’). When used 
for 3D medical image volumes the problem becomes complex by assigning deformation 
vectors to millions of voxels with different physical properties. DIR has been a long-
standing tool in computer vision with its recent surge in popularly due to improvements in 
data storage and computation [52]. Registration algorithms can be defined by four main 
characteristics: i) transformation type ii) image similarity metric iii) regularization, and 
iv) optimization. Many fundamentals of image registration have been explored in the 
textbooks Medical Image Registration by J Hajnal [53] and Numerical Methods for Image 
Registration by J Modersitzki [54]. Other informative journal articles describing the 
fundamentals behind DIR are by Glocker et al. [55] and Oh et al. [56]. 
1.7.3 Transformation 
When two image volumes (referred to as the moving and final image volumes) are 
presented the first question is how to match them together or deform the moving image to 
match the final. The simplest option is to use a combination of affine transformations 
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including translation, rotation and scaling producing a “rigid registration” with the shape 
of objects conserved. As the complexity of the transformation increases more parameters 
are added to explain the local deformation at different points throughout the image. The 
deformation of these points can be driven by different methods and linear combinations 
of spline functions (e.g. B-spline) are commonly used. B-spline methods linearly combine 
different B-spline functions to deform all points from the moving image to the final 
image. Interpolation between control points can also be performed following the 
combined B-spline functions, an example of a B-spline interpolation is shown in Figure 
1-5a. Spline-based transformations are used in multiple studies [57, 58] and within the 
open source Insight segmentation and registration toolkit (ITK) registration software [59]. 
Splines are a parametric model and can be solved rapidly since each point is not solved 
individually with a resulting DVF looking similar to Figure 1-4. 
Different from spline methods the popular ‘Demons’ method is able to represent the DVF 
at each voxel of the volume by calculating a demons force at each voxel based on the 
local intensity gradients. The demons method has been adapted in many commercial 
systems [60-61] because of high-resolution DVFs but has difficulties driving 
deformations in regions of low-intensity gradients. A demons transformation can produce 
fine local deformations as shown in Figure 1-5b for an example of the shrinking of a 
small structure. 
 
Figure 1-5: a) Example of a 1D spline interpolation b) example of demons DVF vector for a small 
object shrinking from the bottom. Produced in MATLAB. 
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To better model physical systems improved algorithms were developed using finite 
element modelling [62] and Hooke’s law to govern the resistance to deformation and 
elasticity of biological tissue. Most medical CT and MRI image studies have important 
organs contoured and can also highlight regions of bones, air and soft tissue all with 
different intrinsic mechanical properties. Applying the different mechanical properties 
from contoured images with finite element methods allowed for a biomechanical model 
for image transformation producing highly accurate results, implemented in the Ray 
station treatment planning systems developed from RaySearch Laboratories [63]. Though 
its results have been promising it currently requires contoured images for the best results, 
which are difficult and time-consuming to produce with daily image guidance. Contoured 
images are used to assign mechanical properties to specific voxels, and to model the 
surface deformations of structures. 
1.7.4 Image similarity 
With a transform applied to the moving image, a measure of image similarity is required 
to evaluate how accurately the deformed volume matches the final volume. There are two 
main categories of image similarity metrics based on landmarks and image intensity 
values. Landmark or feature methods locate important unique regions including corners, 
edges or object centres and try to match their position between the transformed moving 
and final image volume. Though simple to understand, landmark methods are rarely used 
for driving a DIR because of large calculation times and the requirement of the objects to 
be imaged clearly. Methods based on image intensity are more general and have been the 
standard for all DIR algorithms requiring only the intensity values at each voxel. 
Image similarity metrics based solely on image intensity values are the mathematical 
relationships between two data sets, arranged in a 2D or 3D matrix. One of the simplest 
metrics is the sum of squared difference (SSD). 
ܵܵܦ = ଵ
ே
∑ (ܺெ௜ − ܺி௜)ଶே                (1) 
 
Where N is the total number of voxels i, XM and XF are the voxel intensity values for the 
deformed moving (subscript M) and final (subscript F) image, respectively. SSD is very 
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easy to calculate only requiring N operations for any image, but it is limited and has 
difficulties with noisy images and any differences in imaging protocol or modality. To 
improve upon the SSD other metrics are used including normalized cross correlation 
(NCC), equation (2), with standard deviation σ and തܺ being the mean value per image. 
ܰܥܥ = ∑ ଵ
ఙಾఙಷ
(ܺெ௜ − ܺெതതതത)(ܺி௜ − ܺிതതതത)ே              (2) 
 
For cross modality DIR (for example CT to MRI, or CT to CBCT) both SSD and NCC 
metrics can suffer due to non-linear differences in image intensity values in the same 
material (i.e. bone or soft tissue).  
A different approach is the concept of mutual information (MI), evaluating not the image 
intensities but analyzing the “information” present in both images. MI is calculated by 
looking at the probability that intensity values from the moving image match with values 
from the final images. For example, if the probability of value X from the moving image 
matching value Y from the final image is very high, the agreement is consistent. If the 
probability of other value pairs is high, you can assume that the registration is accurate. A 
more in-depth explanation of MI can be found in Hill et al [64]. Any DIR with multi-
modal imaging (e.g.CT-MRI) exclusively uses MI to overcome the conceptually different 
voxels values [65]. 
1.7.5 Regularization  
Applying different image transformations to maximize image similarity can produce 
various solutions that “best” match two images together. Unfortunately, image similarity 
metrics fail to consider the physical limitations of the objects, producing solutions that 
deform across large distances or collapse many voxels down to a single point. To 
constrain the registration process, an additional regularization term is used in conjunction 
with the image similarity. As the image similarity drives the registration towards 
matching both images, the regularization term will penalize certain transformations based 
on the application. For example, registrations of the brain and skull will impose strict 
volume conservation, unlike registrations of the abdomen or thorax which would apply 
regularization to ensure smoothness.  An example of a regularization term  
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ܴ(ܶ) = ߙ ∫‖∇ܶ(ݔ)‖ଶ݀ݔ               (3) 
 
promotes smoothness by penalizing first order derivatives, where T is the transform (or 
DVF) and α is a weighting parameter. 
1.7.6 Different algorithms 
Through various combinations of transformations, image similarity metrics and 
regularization different DVFs will yield significantly different results. Depending on the 
final application or software environment, different commercial vendors have 
implemented their own unique algorithms. Popular commercial products for radiation 
therapy include RayStation (RaySearch laboratories, Stockholm, Sweden), MIM Software 
(Cleveland, OH, USA), Velocity (Varian Medical Systems, Palo Alto, CA). For the 
treatment planning system Raystation the DIR algorithm named ANACONDA (explained 
in more detail by O. Weistrand et al [63]) is incorporated, using a correlation coefficient 
similarity metric and two forms of regularization ensuring smoothness and shape based 
regularization. Shape-based regularization assumes that anatomical regions are defined by 
3D meshes and the DIR must deform the mesh in a consistent and physical manner. Also, 
the ANACONDA algorithm can include contour information both as a penalty term in the 
regularization, or simply to focus the registration to important regions. 
Unlike Raystation, the algorithm from MIM software is less documented but is an 
intensity-based free-form algorithm, using the sum of the squared difference as the 
similarity metric [66]. Velocity uses an intensity based b-spline algorithm, with mutual 
information as a similarity metric [67]. Currently, commercial vendors of DIR do not 
report the specifics of their propriety algorithms, resulting in most DIR products being 
implemented as “black box” systems. Even with the most advanced DIR algorithm 
inaccuracies will be present when attempting to match millions of voxels between image 
studies and the problem gets worse when algorithm specifics are locked within black box 
systems. These inaccuracies can be harmless or lead to miss-registering a tumour to a 
sensitive structure.  
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1.8 Registration error 
Deformable image registration has a vast scope working with deformed image sets, 
comparing time points, or different imaging modalities. Because DIR at first glance can 
appear to accurately register two images, registration errors can be very difficult to spot 
making additional evaluation necessary. For this reason, many studies have been 
published producing different methods or metrics to evaluate the “quality” or accuracy of 
the DIR. The goal of these studies is to provide the user with a means to compare and 
evaluate different registrations and provide information where a particular registration 
algorithm is most accurate.  
The two most common methods for evaluating DIR are comparing contours or 
segmentation and propagated manual landmarks. Contour propagation has always been an 
attractive feature of DIR and comparing the generated contours to expert manual contours 
has been the standard for registration benchmarking. The common metric for contour 
comparison is the DICE coefficient measuring the overlap of two contours and it has been 
used in the majority of studies [68-71]. Unfortunately, contour methods fail to evaluate 
registration performance within structure boundaries which is essential for accurately 
determining accumulated radiation dose. Another common method is comparing the 
propagation of landmark sets produced by experts [72]. This method uses landmarks 
located in two image sets and finds the distances between actual landmarks and DIR 
predicted landmarks in the final image. Landmarks provide discrete measurements of DIR 
accuracy but they need to be located manually. In order to overcome this problem in 
Chapter 3, an automatic method using the scale-invariant feature transform is presented 
and tested against manual and expert landmarks.  
Some early examples of DIR accuracy measures were the inverse consistency or 
transverse consistency errors describing how a DVF mapped the moving image to the 
final image and vice versa [73]. In principle consistency measures are good “warning” 
signs of unrealistic registrations, but can’t adequately predict the magnitude of error as 
shown by Bender et al. with poor correlation to registration errors [73]. Methods looking 
at mechanics-based metrics such as unstable energy by Li et al. [74] yielded improved 
correlation with registration error. Building on the idea of consistency metrics, Saleh et al. 
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developed the distance discordance metric (DDM) [75] that uses registrations between 
images within the same longitudinal study to measure consistency and demonstrated 
higher correlation than the original consistency metrics alone. Other studies attempted to 
use different statistical measures to determine registration uncertainty using bootstrapping 
[76] and the Cramer-Rao bound method [77]. More advanced methods were developed to 
specifically evaluate a DIR with respect to the physical deformation of tissue. For 
example, Zong et al [78] used finite element analysis to simulate the elastic properties of 
soft tissue to measure the internal forces. 
Predominantly DIR evaluation methods are derived to compare and contrast different 
algorithms to best determine the most accurate and efficient algorithm for specific 
applications. This approach has been followed in multiple studies comparing different 
algorithms by comparing their DICE scores, or landmark registration errors for given test 
sets [79, 80]. Work by Kirby et al. constructed realistic 3D phantoms for the head and 
neck and male pelvis to evaluate several DIR algorithms [81, 82]. What needs to be 
determined is how this error affects the final results for a dose accumulation and if 
uncertainty bounds can be added to any final result. Figure 1-6, an example of using DIR 
to match a single point on the boundary of the rectum from two CT studies shows how 
the dose results can vary significantly depending on the registration error. 
 
Figure 1-6: Example of the effect of registration error. Colour map is the radiation dose. Point A) 
miss-registration but still on the boundary, B) miss-registration still within boundary and C) miss-
registration with same dose level. 
These errors may not be significant for a single registration, but the errors can cumulate 
as the radiation dose is accumulated from multiple studies. A study by Risholm et al. 
demonstrated a DIR algorithm that inherently produced the uncertainty of every vector 
19 
 
 
within the DVF [83]. Using this algorithm, uncertainty bounds could be added to any 
final results. For example, in a later study, they added uncertainty bounds to a dose 
accumulation showing their impact on the final accumulated dose distribution [84]. 
Though the work by Risholm et al. demonstrated the possibility of applying uncertainty 
information, it was only possible with their custom DIR algorithm that was not designed 
for clinical practice. What is required for clinical practice is for commercial DIR 
algorithms to provide DIR uncertainty and accuracy information for each DVF to provide 
realistic results? In chapter 4 a method of incorporating predicted DIR uncertainty into a 
commercial DIR algorithm is demonstrated. Having a characterization of the uncertainty 
of DIR with deformable dose accumulation can provide physicians with useful 
information for making a decision on plan adaptation and dose prescriptions. Therefore, 
including registration uncertainty in the dose accumulation process can provide a more 
accurate account of radiation delivery throughout a multi-fraction treatment, producing 
more powerful predictive models of disease control and normal tissue complications. 
With more powerful predictive models treatment options can be determined uniquely for 
each patient and their desired outcome creating personalized medicine in radiotherapy. 
1.9 Decision making in radiation therapy 
Since 1951, when the first Co-60 radiation treatment unit was used in London, Ontario for 
cancer care, tremendous progress in technology has occurred. The huge amount of 
clinical evidence has been obtained through clinical trials with patient participation, 
laboratory experiments and various comparative studies of treatment outcomes reported 
in scientific journals. In practice, treating physicians are often deciding on the best 
possible treatment of patients quickly based primarily on the physician’s education and 
personal experience. Yartsev and Mackie [85] proposed a scheme for decision making 
that involves creating a model for radiation therapy based on a large and constantly 
growing database of patient’s personal features, parameters of treatment, clinical 
outcomes and patient’s preferences. An important aspect of such a model is quality data 
accounting for all elements of treatment to facilitate machine learning methods and allow 
the models to incorporate incoming patient data. In this thesis, we consider several key 
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components of the decision-making process, schematically presented in Figure 1-7 
highlighting the contributions from each chapter of the thesis.  
This schematic describes the connection of the planning data (left side) and the patient 
data (right side) and the different processes required to link them together described 
through specific chapters. The first link is the modelling of patient data to determine 
optimal treatment plans for the desired patient outcomes. In Chapter 2 a multivariable 
model is produced linking patient, treatment and outcomes data producing two clinical 
nomograms to help guide physicians with treatment decisions. The second link is between 
the planning image and treatment images provided through deformable image registration 
and image guidance (IGRT). DIR is a key element of this link since all daily changes are 
deformable. Though DIR is an excellent and necessary tool, it has unknown inaccuracies 
that need to be considered when used clinically. In Chapter 3 an automatic DIR 
evaluation method was presented allowing DIR to be evaluated routinely whenever it is 
applied.  
The third link is determining the real delivered dose from the planned dose using daily 
images and deformable image registration for dose accumulation. Similar to the second 
link deformable image registration is required and its accuracy needs to be considered in 
the final dose accumulation. Chapter 4 created a method to incorporate DIR uncertainty 
into the dose accumulation process, to determine what dose was actually delivered. The 
final link is between the original treatment plan and the adapted treatment plan initiated 
after significant anatomy change was observed. In Chapter 5 a method for quantitatively 
evaluating the necessity of plan adaption is presented in order to provide more accurate 
and consistent plan adaptation strategies. The thesis chapters each provide different 
necessary elements required to incorporate patient data to determine patient outcomes 
from their cancer treatment. 
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Figure 1-7: Schematic for outcome-driven decision making in personalized radiotherapy. 
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1.10 Research goals and objectives 
The research outlined in this thesis focuses on two main goals i) to construct a method of 
including radiation treatment parameters for prediction of clinical outcomes ii) to provide 
the methods of tracking accumulated dose in multi-fraction treatment with known 
registration uncertainty. These goals were achieved through the following objectives 
including the modelling of patient survival in radiation therapy and the practical 
applications of DIR: 
1. Find the significance of treatment and pre-treatment parameters in modelling patient’s 
overall survival and construct nomograms. 
2. Produce and evaluate an automatic landmark generation method and test against both 
amateur and expert manual landmarks. 
3. Determine the effect of registration error on measuring the daily dose using DIR. 
4. Evaluate the ability to decide when to adapt a treatment plan for head and neck cancer 
patients using DIR without a dose recalculation. 
1.11 Thesis outline 
1.11.1 Modelling of overall survival for hepatic carcinoma or liver 
metastasis receiving radiotherapy (Chapter 2) 
There are many parameters influencing treatment success in liver cancer including patient 
and treatment parameters. In this study, patients diagnosed with hepatic carcinoma and 
liver metastasis were analyzed with multivariable Cox regression of overall survival. The 
results were two nomograms for primary hepatic and metastatic patients demonstrating 
the impact of radiation prescription and other patient parameters on overall survival. This 
chapter is based on the publication in the Journal of Future Oncology titled “A 
multivariable model to predict survival for patients with hepatic carcinoma or liver 
metastasis receiving radiotherapy” by Jason Vickress, Michael Lock, Simon Lo, Stewart 
Gaede, Aaron Leung, Jeff Cao, Rob Barnett, and Slav Yartsev. 
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1.11.2 Automatic landmark generation for evaluation of deformable image 
registration accuracy (Chapter 3) 
DIR has become a pivotal tool in radiation therapy for contour propagation, anatomical 
assessment and dose accumulation even though errors are common and poorly 
characterized. Different DIR evaluation techniques are used in practice including contour 
evaluation and landmark matching but both require significant user input and are difficult 
to apply routinely. We developed a method of automatically generating landmarks using 
the scale-invariant feature transform and tested it against both amateur and expert 
landmark sets. The results of this work were published in the Journal of Physics in 
Medicine and Biology titled “Automatic landmark generation for deformable image 
registration evaluation for 4D CT images in lung” by Jason Vickress, Jerry Battista, Rob 
Barnett, John Morgan, and Slav Yartsev. 
1.11.3 Dosimetric impact of deformable image registration error in radiation 
therapy (Chapter 4) 
DIR has been introduced to track anatomical changes between daily fractions to 
accumulate the actual radiation dose. Unfortunately, inherent errors in DIR can lead to 
significant changes in dosimetric analysis and need to be accounted for in any analysis. In 
this study, we derived a method to incorporate predicted registration uncertainty into the 
final dosimetric analysis using expert landmarked lung 4DCT studies. This chapter is 
based on the publication in the Journal of Physics in Medicine and Biology titled 
“Representing the dosimetric impact of deformable image registration errors” by Jason 
Vickress, Jerry Battista, Rob Barnett, and Slav Yartsev. 
1.11.4 Daily assessment of dose change using deformable image registration 
without dose-recalculation (Chapter 5) 
Adaptive radiation therapy has been successful for many treatment sites where anatomical 
changes are frequent and can cause the dose distribution to deviate from what was 
planned. Currently plan adaptation is triggered by manual evaluations of daily CBCT 
images by therapists, physicists and oncologists leading to either plan adaptation or to 
continue the original plan.  Using DIR and the planned dose distribution an automatic 
method for determining the necessity of plan adaptation was developed and tested against 
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the gold standard of using a new CT study with a new dose calculation. The results of this 
method have been submitted to the Journal of Applied Clinical Medical Physics titled 
“Online daily assessment of dose change in head and neck radiotherapy without dose-
recalculation” by Jason Vickress, Jerry Battista, Rob Barnett, and Slav Yartsev. 
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Chapter 2 
 
2 A multivariable model for the prediction of survival for 
patients with hepatic carcinoma or liver metastasis 
receiving radiotherapy 
This chapter has been previously published as “A multivariable model for the prediction 
of survival for patients with hepatic carcinoma or liver metastasis receiving radiotherapy” 
published in Future Oncology, 13 (1), 19-30 by Jason Vickress, Michael Lock, Stewart 
Gaede, Aaron Leung, Jeff Cao, Rob Barnett and Slav Yartsev. Permission to reproduce 
this article was provided by the publisher and presented in Appendix A.3. Additional 
explanation of clinical tools and parameters is presented in Appendix B. 
2.1 Introduction 
Liver cancer, as of 2013, has the sixth highest incidence rate with the third worst survival 
rate worldwide [1]. Historically, radiation therapy has played a limited role in the 
treatment of liver cancer because of the normal liver’s inherent radiosensitivity. However, 
studies on the radiobiological effects of radiation on the liver provided the ability to 
determine suitable radiation dose levels, and on how to select patients appropriate for 
radiation have resulted in an increasingly important role for radiation [2].  
The advent of stereotactic body radiotherapy (SBRT) made possible the delivery of high 
radiation doses to the target while sufficiently sparing the surrounding healthy tissues, 
which is critical for the radiotherapy of liver cancers. Studies have shown significant 
benefits to local control and survival [3-7] using more intensive treatments at the cost of 
potential toxicity [8,9].  Recently, two comprehensive summaries of the literature have 
established the current knowledge on hepatic radiation. Klein et al. reviewed 
hepatocellular carcinoma radiotherapy demonstrating a local control rate of 80-90% for 
selected patients with smaller tumours and no portal venous thrombosis [10]. This 
thorough review also confirms that low rates of adverse events have been found. 
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However, the review also confirms the wide variation in treatment technique and patient 
selection criteria for radiation. This makes interpretation and comparison of trials 
difficult. For example, comparison of trial A that included patients with a better outcome 
than trial B would result in the inappropriate conclusion that trial A treatment technique 
was better.  Nomograms and risk stratification play an important role in allowing a 
comparison of study outcomes and selection of the most appropriate patients for future 
trials.   
For metastatic disease, a similar review performed by Hoyer et al. plus an international 
survey demonstrated similar results and made similar recommendations to the 
hepatocellular review. For metastatic lesions, 1-year local control rates ranged widely 
from 23% to 95% likely due to a lack of consensus on the selection of patients [11, 12]. 
Despite multiple well-performed studies, radiation is not included in many of the major 
guidelines used to treat liver lesions [13]. Why is this? First, large-scale multicentre trials 
in this patient group have not been performed despite being a cancer with one of the 
highest death rates and a research priority. Trial accrual is often difficult due to the rapid 
progression of the disease, variability in treatment availability and the patient’s reluctance 
to be randomized to a treatment arm with a known poor outcome or one with evidence 
collected primarily from relatively small case series. Second, treatment-related factors 
have not been properly established. Therefore, individual centres are performing liver 
radiation using a wide variety of strategies especially variable doses, fractionation and 
patient selection [12]. Third, the patient population is very heterogeneous with respect to 
presentation, previous treatments, the extent of disease, and location of disease requiring 
larger sample sizes. A larger number of patients need to be investigated to be able to 
statistically reveal important information from such a heterogeneous population. Lastly, 
current analyses have not always accessed the vast amount of physics and dosimetric data 
available and have previously focused on clinical and imaging parameters, such as alpha-
fetoprotein (AFP) or tumour size. Furthermore, patient numbers in individual centres are 
insufficient to provide the higher number of data points required to assess the potentially 
numerous critical parameters such as appropriate dose [14].  
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To address these factors, our ability to properly combine and analyze data collected from 
multiple institutions is critical; this will lead to practical treatment strategies based on 
information from comparable groups and clinical trials where outcomes can be assessed 
as better or worse than previously published trials. The use of a predictive tool will assist 
in standardizing patient selection based on risk group, thereby providing a greater ability 
to accrue to multicenter trials and compare outcomes. This methodology may also 
promote the inclusion of physics and dosimetric parameters not usually included in 
nomograms. Finally, a tool to provide consistent outcome data in this heterogeneous 
population will provide information a) on which patients may benefit from radiotherapy 
to referring physicians, and b) for administrators, clinical trialists and guideline 
developers on the expected outcome of patients receiving radiation.  
Using large collections of patient data, clinical models of survival and recurrence have 
been successfully developed for multiple treatment sites in radiation therapy [15, 16], 
including liver cancer [17]. In this publication, we develop a multivariable prognostic 
model for predicting overall survival after radiation therapy for patients with primary and 
metastatic liver cancer based on data from one of the largest published liver databases as 
proof of principle of this methodology. 
2.2 Methods 
2.2.1 Patient population 
The patient population consisted of 195 patients receiving radiation treatment for 
hepatocellular carcinoma (HCC) or liver metastasis (Mets) in a comprehensive tertiary 
cancer facility from 2004 to 2015, with demographics shown in Table 2-1. Patients were 
considered for the study if they were ineligible for standard treatment (TACE, surgery or 
RFA) and received radiation treatment, but were excluded if they received low dose 
palliative treatment.  Sorafenib was the principle chemotherapy provided. However, many 
of the patients were entered into trial prior to the release of sorafenib. Therefore, 
chemotherapy included the previous standard which was doxorubicin.  Study endpoints, 
such as overall survival (OS) and disease-free survival (DFS), were collected from patient 
charts and electronic records. All data collection and analysis was approved by the local 
ethics board. 
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Table 2-1: Patient demographics   
Characteristic HCC (N = 66) Mets (N = 129) 
Age (years) 70 ± 12 65 ± 12 
Sex 
   Male 56 (85%) 67 (52%) 
   Female 10 (15%) 62 (48%) 
tumour volume (cm3) 384±447 351±870 
# of lesions 
   1 45 (68%) 65 (50%) 
   2 7 (11%) 32 (25%) 
   3 10 (15%) 19 (15%) 
   >3 4 (6%) 13 (10%) 
CP Grade 
   A 42 (64%) 99 (77%) 
   B 22 (33%) 28 (22%) 
   C 2 (3%) 2 (1.5%) 
   unknown 0 (0%) 2 (1.5%) 
Bilirubin 21.6±29 17±32.7 
Serum Albumin 35±6 38±6 
Ascites   
   Y 19 (29%) 12 (9%) 
   N 47 (71%) 117 (91%) 
primary site (N = 130)   
   colorectal carcinoma  52 (40%) 
   cholangiocarcinoma  22 (17%) 
   neuroendocrine carcinoma 10 (8%) 
   breast carcinoma 10 (8%) 
   non-small cell lung carcinoma 10 (8%) 
   pancreatic carcinoma 7 (5%) 
   renal cell carcinoma 3 (2%) 
   metastatic melanoma 3 (2%) 
   gastric carcinoma 3 (2%) 
   esophageal 3 (2%) 
   other 6 (4%) 
previous treatments  
   chemo embolization 17 (26%) 7 (5%) 
   I-131 lipiodal  7 (11%) 6 (5%) 
   radiofrequency ablation 3 (5%) 9 (7%) 
   chemotherapy 6 (9%) 95 (74%) 
   liver resection 5 (8%) 32 (25%) 
   previous abdomen radiation 0 9 (7%) 
HCC - hepatocellular carcinoma, Mets - metastatic disease, CP- Child-Pugh 
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2.2.2 Radiation treatment 
Patients received radiation treatment using Volumetric Modulated Arc Therapy (VMAT), 
fixed beam Intensity Modulated Radiation Therapy (IMRT), three-dimensional conformal 
radiotherapy (3DCRT), or helical Tomotherapy (Tomo). Radiation dose prescriptions 
varied between 15 and 88 Gy in 5 to 35 fractions using a radiobiologically-guided 
prescription program similar to the radiobiological NTCP dose calculation published by 
Dawson [18, 19]. Patients receiving 5 or 6 fractions were irradiated every other day, and 
the remaining patients were treated daily for 10-35 fractions. Most patients were treated 
using a respiratory gated and image-guided technique. The remainder of patients, who 
were either unable to hold their breath or had irregular breathing, were treated with full 
respiratory motion using a complete internal target volume (ITV). Gross tumour volume 
(GTV) delineation was performed on the primary planning contrast-enhanced 4DCT 
images.  
2.2.3 Statistical analysis 
The effect of each variable on OS was evaluated using the Cox proportional hazards 
model. Continuous variables entered into the model were biologically effective dose to 
the tumour (α/β = 10 Gy) in 2 Gy fractions (EQD2), volume of normal liver receiving 
more than 24 Gy total dose (V24), GTV, bilirubin count, serum albumin, prothrombin, 
Child-Pugh (CP) score and age. Dichotomous variables; ascites, prior chemotherapy, and 
colorectal primary disease, were assigned values of 0 or 1. Hepatic encephalopathy was 
not entered into the model because only 3 patients exhibited symptoms. For univariate 
analysis, patients were stratified into several subgroups based on (i) liver function (CP A 
vs CP B+C) and (ii) primary HCC vs metastasis (Mets). Hazard ratios (HR) were defined 
by dividing the partial hazard of the third quartile by the first quartile to get an effect 
across the spectrum of clinical values.     
Identification of the most useful variables was performed with univariate Cox 
proportional hazard modelling, followed by multivariable analysis performed using a 
stepwise selection with a significance level of 0.05. Once the most significant variables 
were identified, nomograms predicting OS at one year were assembled for both HCC and 
Mets subgroups. Nomograms were evaluated by a concordance index (C-index) [20] 
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using four-fold cross-validation with 200 iterations to reduce bias. The C-index measures 
the discrimination of the data and the values range from 0.5 (no discrimination) to 1.0 
(perfect discrimination). Model calibration was performed by grouping patients according 
to their nomogram-predicted probabilities and comparing them against the observed 
Kaplan Meir Overall Survival estimate, presented as calibration curves. The goodness of 
fit of the calibration curves are evaluated by the Hosmer-Lemeshow (HL) test, with a 
value greater than 0.05 having a strong fit. 
2.3 Results 
2.3.1 Patient demographics 
The heterogeneous patient population used in this study allowed us to investigate the 
effect of a large number of parameters on the outcome of radiation therapy (Table 2-1). 
The majority of patients had liver metastases (n = 129), but the number of patients with 
primary HCC (n = 66) was still sufficient for statistical comparison.  Because of 
developing technologies within 2004-2015, the radiation treatment techniques evolved 
from 3DCRT (n = 58) to IMRT (n = 68), to VMAT (n = 62) and Tomo (n=7). The 
prescribed planning tumour volume (PTV) doses had a wide range of 15 – 88 Gy (median 
45 Gy). Treatment schedules were either treated every other day for 5-6 fractions (58% of 
patients) or daily treatment for 10-35 fractions (42% of patients). Patients had varying 
liver functions with CP scores ranging from 5 to 10 (median 6). The overall survival for 
patients with HCC or liver metastasis is described by the Kaplan Meir curve in Figure 2-1 
with 12/66 and 33/129 missing events for HCC and liver metastasis groups respectively 
with a median follow up of 37 months. 
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Figure 2-1: Kaplan--Meir survival curves for patients with HCC and secondary liver metastasis. 
2.3.2 Effect of liver function 
To investigate the impact of liver function before radiation treatment, patients were 
stratified into two groups based on their overall pre-treatment liver function, as defined by 
CP score A vs score B+C. Cox regression analysis was performed on both patient groups 
and the effect of radiation treatment parameters and liver function on OS is shown in 
Table 2-2. For patients with a CP score A, increased radiation dose (EQD2) showed a 
significant survival benefit. In both CP A and CP B+C groups, poor liver function 
parameters (CP Score and Serum Albumin) and larger GTV size had a negative effect on 
overall survival.  
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Table 2-2: Univariate Cox regression analysis of two CP score groups for OS. 
  CP-A CP B/C 
Factor HR 95% CI p-value HR 95% CI p-value 
GTV 1.18 1.03 - 1.34 0.014 1.19 1.07 - 1.32 0.001 
EQD2Gy 0.61 0.46 - 0.8 < 0.001 0.84 0.49 - 1.45 0.538 
V24 0.94 0.70 - 1.25 0.654 1.20 0.81 - 1.79 0.366 
Bilirubin 1.14 0.87 - 1.5 0.326 1.12 1.06 - 1.18 < 0.001 
Serum Albumin 0.54 0.37 - 0.79 0.001 0.41 0.27 - 0.63 < 0.001 
Ascites 1.34 0.58 - 3.08 0.487 1.54 0.84 - 2.82 0.160 
Prothrombin 1.22 0.92 - 1.61 0.167 0.87 0.74 - 1.02 0.080 
CP Score 2.65 1.18 - 5.97 0.018 3.95 2.02 - 7.75 < 0.001 
Age 1.06 0.84 - 1.35 0.617 0.77 0.48 - 1.21 0.252 
# of Lesions 0.92 0.79 – 1.08  0.33 0.91 0.74 – 1.11 0.35 
Extrahepatic 1.33 0.91 – 1.95 0.14 1.63 0.89 – 2.98 0.11 
Chemo 0.95 0.65 - 1.39 0.795 0.82 0.45 - 1.51 0.532 
GTV – gross tumour volume, EQD2Gy – equivalent dose in 2 Gy fractions, V24 – the volume of normal liver receiving 
24 Gy 
CP – child pugh 
2.3.3 Primary HCC vs liver metastasis 
Based on our analysis, two nomograms were constructed for the OS of patients treated for 
a primary HCC (n = 66) or liver metastasis (n = 129). The results of the univariate 
variable selection and multivariate modelling are presented in Table 2-3. The final model 
variables are presented in the multivariable columns of Table 2-3, with the full model 
described in Table 2-4. 
Table 2-3: Univariate and multivariable Cox regression results for both HCC and metastasis. 
HCC 
Univariate Multivariate 
Factor HR 95% CI p value HR 95% CI p value 
GTV 1.68 1.3 - 2.17 < 0.001 1.81 1.42 - 2.32 0.001 
EQD2Gy 0.51 0.34 - 0.78 < 0.001    
V24 1.28 0.9 - 1.81 0.17 
Bilirubin 1.34 1.15 - 1.56 < 0.001 1.31 1.11 - 1.55 0.001 
Serum 
Albumin 0.39 0.25 - 0.62 < 0.001 0.39 0.23 - 0.67 < 0.001 
Ascites 2.18 1.16 - 4.09 0.02 
Prothrombin 0.95 0.81 - 1.12 0.55 
CP Score 2.25 1.49 - 3.41 < 0.001 
Age 1.01 0.74 - 1.39 0.93 
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# of Lesions 1.10 0.84 - 1.45 0.48    
Extrahepatic 1.00 0.45 - 1.69 0.69    
Chemotherapy 1.00 0.34 - 2.25 0.78    
Metastasis 
Univariate Multivariate 
Factor HR 95% CI p value HR 95% CI p value 
GTV 1.12 1.05 - 1.19 < 0.001 1.07 1 - 1.14 0.04 
EQD2Gy 0.66 0.5 - 0.87 < 0.001 
V24 0.86 0.61 - 1.22 0.40 
Bilirubin 1.15 1.1 - 1.2 < 0.001 1.11 1.06 - 1.17 < 0.001 
Serum 
Albumin 0.43 0.31 - 0.58 < 0.001 0.49 0.36 - 0.68 < 0.001 
Ascites 1.00 1 - 1 0.01 
Prothrombin 1.04 0.97 - 1.12 0.29 
CP Score 1.64 1.35 - 1.99 < 0.001 
Age 1.08 0.83 - 1.39 0.57 
# of Lesions 0.87 0.77 - 1.04 0.16    
Extrahepatic 1.79 1.18 - 2.71 0.01    
Chemotherapy 0.90 0.58 - 1.4 0.64    
Colorectal 0.67 0.44 - 1.01 0.01 0.62 0.4 - 0.96 0.03 
GTV – gross tumour volume, EQD2Gy – equivalent dose in 2 Gy fractions, V24 – the volume of normal liver receiving 
24 Gy, CP – child pugh 
Table 2-4: Model results including β values, units and 6 months / 1-year baseline cumulative hazard 
ratio. 
HCC Model 
Variable Units  β 6 month λ0 1 year λ0 
Bilirubin count  mg/dl 0.0203 
5.91 11.80 Serum Albumin mg/dl -0.104 
GTV cm3 0.00131 
Metastasis Model 
Variable Units  Beta 6 month λ0 1 year λ0 
Bilirubin count mg/dl 0.0154 
11.83 23.07 Serum Albumin mg/dl -0.0889 
Colorectal primary site yes (1), no (0) -0.4774 
GTV cm3 0.000296 
λ0 indicates cumulative baseline hazard ratio, GTV – gross tumour volume 
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The nomogram predicting OS at six months and at one year for patients with a primary 
HCC is displayed in Figure 2-2a. The greatest effect on the patient’s survival is predicted 
by liver function parameters (bilirubin and serum albumin). Similar trends are found in 
the nomogram for metastases in Figure 2-2b, with a lower overall survival than HCC.  
For model evaluation, the concordance values were found to be 0.74 for the HCC model 
and 0.68 for the metastasis group after four-fold cross-validation, performed 200 times 
showing good discrimination.  
 
Figure 2-2: Nomogram for the probability of six months and one-year survival for patients with (a) 
HCC and (b) liver metastasis. 
The calibration curves for both models are shown in Figures 2-3 and 2-4 (with the result 
of the HL test) for the HCC and metastasis models respectively. Calibration curves 
yielded good calibration abilities for both six months and one-year survival for the HCC 
model (Figures 2-3a and 2-4a) and the Mets model (Figures 2-3b and 2-4b). 
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Figure 2-3: Kaplan--Meir survival curves for HCC (a) and  Mets (b) showing the lower (solid) and 
higher (dashed) risk groups obtained by the multivariate models. 
 
Figure 2-4: Calibration curves for predicting 6-month survival for HCC (a) and Mets (b). The 
goodness of fit was calculated using the HL test yielding a p-value of 0.1693 and 0.0412 for HCC and 
Mets respectively. 
Kaplan Meir curves between high and low-risk patients (as determined by the model 
separated by the median hazard ratio) presented in Figure 2-5, showed significant 
separation for both the HCC and Mets models.  
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Figure 2-5: Calibration curves for predicting 1-year survival for HCC (a) and Mets (b). The goodness 
of fit was calculated using the HL test yielding a p-value of 0.211 and 0.077 for HCC and Mets 
respectively. 
2.4 Discussion  
2.4.1 Patient demographics 
Liver cancer affects a wide range of patients with different underlying pathologies, 
treated with different treatment strategies and with varied functional status creating a very 
heterogeneous patient population that is typically seen in the literature. Though 
heterogeneous patient data causes problems with generalizability and requires large 
sample sizes to determine predictive variables; when we have sufficient patient numbers, 
heterogeneous treatment data provides an opportunity to clarify questions such as what 
dose should be prescribed as many different prescriptions are used in clinics. 
Heterogeneous data in this study enabled the analysis of HCC and metastasis patients 
with different liver functions (CP-A, or B+C) in one of the largest published datasets in 
the literature. This dataset included varying dose prescriptions (20 to 70 Gy), and 
fractionations (5 to 25 fractions), which created different biological effective doses and 
allowed for the analysis of the benefits of different dose prescriptions.  
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2.4.2 Liver function 
A patient’s liver function before the start of radiation therapy is known to be a strong 
predictor of OS [21]. The analysis from the Cox regression for OS shows a significant 
difference between patients with a Child-Pugh score of A vs B+C. Patients with CP A 
had a significant survival advantage with increased radiation dose to a tumour, whereas 
patients with grade B+C did not. Previous work on patients with CP B+C has shown 
similar results regarding the poor response to radiation therapy [21], with similar effects 
from tumour size and CP score.  Increased CP score post radiation therapy has also been 
shown as a strong predictor of overall survival [22]. Poor liver function and large tumour 
size correlated with decreased survival in all cases. However, only patients with better 
liver function showed a significant increase in survival due to higher radiation dose. 
Therefore, these data suggest that if patients have a poor liver function (defined as CP 
B+C), clinicians would provide better care by not dose escalating and unnecessarily 
risking toxicity. For those with good liver function, dose escalation is an important factor 
for improved survival. Further research is required to determine the appropriate dose. 
2.4.3 Nomogram 
The nomogram in Figure 2-2a for patients with HCC describes the effect of liver function 
and tumour size as major factors in determining patient survival. The nomogram 
demonstrates that liver function and tumour size are much more significant compared to 
an increase in radiation dose. With an average C-index of 0.74, which is substantial given 
the heterogeneous nature of the dataset the model for HCC is accurate in predicting OS. 
For example, the six months and one year OS probability would be 28% and 9%, 
respectively for an HCC patient with a bilirubin count of 40 mg/dl, serum albumin 30 
g/dl, GTV volume of 500 cm3.  For a patient with a bilirubin count of 30 mg/dl, serum 
albumin 30 g/dl and GTV volume of 300 cm3 six months and one year OS would be 50% 
and 26%. After reviewing models predicting OS for HCC patients after non-radiation 
treatments, this radiotherapy nomogram falls within a similar C-index range with 
chemoembolization 0.84 [23], immunotherapy 0.698 [24] and liver resection surgery 0.66 
[25]. All these models share the same large weightings on the patient’s liver function pre-
treatment. Our model also has similar results to the prognostic score ALBI (validated on a 
larger cohort of 2599 patients) [26] demonstrating the significance of Serum Albumin and 
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Bilirubin in predicting overall survival for HCC patients, without the other factors in the 
Child-Pugh score. We are unaware of any nomograms for liver cancer radiotherapy and 
believe our model is the first to be created for patients receiving radiation therapy for 
hepatocellular carcinoma.  
The metastasis model in Figure 2-2b with an average C-index of 0.68 is less accurate than 
the HCC model which is expected given the more complex and heterogeneous nature of 
the metastatic disease. This fact is further emphasized from the HL test on the calibration 
curves with values close to 0.05 showing a worse fit than for the HCC model. Our 
analysis showed that increased radiation dose is not a significant factor in predicting 
patient survival.  A previous study [27] has created a nomogram predicting OS for liver 
metastasis with an area under the curve (AUC) value of 0.83, but it included different 
liver parameters and had no treatment information. The trial focused on a select and 
relatively homogenous subpopulation of liver metastases with external validation. The 
trial assessed only the subpopulation of colorectal patients treated with selective internal 
radiation therapy. Our model is more generalizable and attempts to include a broader 
range of parameters. In particular, the effect of treatment parameters, especially 
prescription dose, to help determine when aggressive treatment is warranted and what the 
patient prognosis may be with radiation. We believe our nomogram is the first to be 
created for liver metastases patients treated with external beam radiation.  
2.4.4 Potential limitations 
Although our model was shown to have comparable accuracy to other models created for 
the treatment of liver malignancies, the heterogeneity of the data results in decreased 
accuracy and ability to address specific subgroups. Therefore, despite being based on one 
of the largest published databases, this model would benefit from more data. Data accrued 
from multiple centres using different dose regimens and constraints would provide the 
heterogeneity in data and sufficient sample size required for detailed analysis of 
subgroups. Using patient sample sizes of 66 for HCC and 129 for Mets can create useful 
models for predicting survival using only four variables. However, there may be other 
undiscovered variables that could improve the predictive ability of these models. With 
larger sample sizes, we can also develop nomograms for specific subgroup such as 
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cholangiocarcinomas or those patients heavily pretreated prior to radiation versus those 
referred early in their natural history. In this model, they are grouped together within the 
Mets group. Validation was successfully performed using a four-fold cross-validation, 
performed in 200 different random combinations, but external validation with a different 
data set is recommended. Determining the true accuracy of this model will require 
external validation, from an equivalent population of HCC and Mets patients, which is an 
aim for future work since the c-indexes for both models are likely to be lower in a 
validation set.  
2.5 Conclusion 
Two models in the form of practical nomograms were constructed for HCC and liver 
metastasis patients to help predict overall survival. The nomograms may help clinicians 
better select appropriate treatment strategies and provide prognostic information for 
patients. The nomograms provide more practical and effective use of available data from 
patients treated for liver cancer. Our conclusion that dose escalation is beneficial only for 
patients with good liver function (CP score A) but not CP B+C patients is also useful 
clinical information. Overall this study presents new tools for the selection of appropriate 
treatment options for patients diagnosed with liver malignancies. 
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Chapter 3 
 
3 Automatic landmark generation for deformable image 
registration evaluation for 4D CT images of lung 
This chapter has been previously published as “Automatic landmark generation for 
deformable image registration evaluation for 4D CT images of lung” published in the 
journal Physics in Medicine and Biology, 61(20), 7236 by Jason Vickress, Jerry Battista, 
Rob Barnett, John Morgan and Slav Yartsev. Permission to reproduce this article was 
provided by the publisher and presented in Appendix A.4. Additional details about the 
Scale Invariant Feature Transform (SIFT) is presented in Appendix C.  
3.1 Introduction 
Medical imaging has become a large focus in health care across both fields of diagnosis 
and therapy. Extensive longitudinal imaging studies require reliable and accurate image 
registration for scientific analysis. In diagnostic applications, changes in tissue 
distribution over time helps assess the progression or regression of disease prior to and 
following treatment. Another example is the need to track radiation dose accumulation 
quantitatively across a multi-fraction treatment where sharp dose gradients transform 
small geometric displacements into potentially large dose errors in the cumulative dose. 
With advancements in computing, many image registration algorithms and software 
platforms have been developed to perform such tasks. Unfortunately, each commercial 
product has hidden features and variable performance creating registration inaccuracies 
which impact the quality of any geometric or dosimetric analysis [1, 2]. In modern 
clinical practice, simple rigid registration methods are being replaced by more 
sophisticated deformable image registration (DIR) creating a large demand for reliable 
evaluation techniques that assess the accuracy of the deformation field and its effect on 
the radiation dose distribution.  
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Evaluation of image registration methods is difficult since it requires a “ground truth” 
benchmark derived from biophysical modelling, mechanical phantoms or landmark sets 
established by expert interpretation of paired images. The landmark method is currently 
the most popular, but it is very time-consuming as indicated in a study by Castillo et al. 
[3] where an average of 12 hours per computed tomography (CT) study was required to 
create high-quality landmarks in the lung. Another important factor is the accuracy or 
appropriateness of the landmark which can be limited by observer bias and/or poor image 
quality. 
Many methods that locate landmark pairs between images automatically have been 
developed [4, 5] with the most promising results from the Scale Invariant Feature 
Transform (SIFT) algorithm [6]. Although SIFT algorithms have been shown to 
accurately locate landmarks in 2D images they have been less successful for 3D medical 
image studies [7]. Some of these problems include matching similar, non-unique 
landmarks and localization of the specific points within the 3D image space. Even with 
demonstrated improvements in the accuracy of SIFT [8, 9], limitations persist, especially 
in crossing imaging modalities such as matching diagnostic CT and cone-beam CT 
images acquired on radiotherapy machines.   To improve both the resource-intensive 
nature of manual landmark selection and SIFT pitfalls and limitations, we present a 
hybrid solution involving straightforward manual editing of results obtained initially by a 
rapid SIFT algorithm. As DIR becomes more popular in the field of clinical evaluation, 
quality assurance, and “big data” mining, validation techniques need to be developed to 
ensure that matching landmarks are truly homologous and located correctly. Automatic 
landmark creation approach is an attractive option for DIR and its evaluation [10] if it is 
shown to have comparable accuracy and usability to manual landmarks. In this study, we 
compare an automatic landmark method to conventional manual landmarking, and high 
quality (gold standard) landmark sets to demonstrate that automated algorithms can 
replace manual landmarks for the validation of DIR. An example using 4DCT datasets of 
the lung at different respiration phases is used to illustrate the principles and advantages. 
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3.2 Methods  
Ten thoracic 4DCT studies were obtained from the “dir-labs” group (http://www.dir-
lab.com/) for use in this study. Three methods of landmark selection on the 0% and 50% 
phases of respiration were tested: manual, SIFT, and SIFT with manual correction (SIFT-
M). Each landmarking method was compared to a landmark set produced by the dir-labs 
group for these images, which was considered as the gold standard (GS), having been 
validated in multiple publications [3]. The GS landmark set contained 300 landmark pairs 
manually selected between the 0% and 50% respiratory phases. 
3.2.1 Manual 
An in-house software tool was created in MATLAB® (version r2015a, MathWorks) to 
facilitate manual landmark selection and matching across both phases of a 4DCT study 
(0% and 50% phases). The tool allows users to search through slice images and, after 
applying a pre-defined window and level, to locate unique matching pairs of anatomical 
points across both images. Two landmark sets were created independently by two 
observers, to mitigate effects of observer bias. Three rules were outlined for the selection 
and definition of unique landmark pairs: (1) pairs must be at unique locations in three 
dimensional spaces, (2) pairs must be surrounded by lung parenchyma tissue and not be 
near or defined by an edge, (3) a unique CT feature can only be landmarked once. For 
practical reasons, each observer was limited to a maximum of 300 landmarks per 4DCT 
study, and four hours of work per study. 
3.2.2 SIFT 
Automatic landmark selection was performed using a modified version of the SIFT 
algorithm based on the original work of Lowe [6] for 2D images, starting with a double 
size image with three octaves each having three levels per octave. We adapted the SIFT 
algorithm to 3D medical CT images using the methods suggested by Allaire et al. [8] not 
including full landmark re-orientation. Specific parameters selected for the algorithm 
included σ = 1.1 for the Gaussian scaling, Hmax = 7 for edge removal, rthresh = 0.01 for 
contrast selection. Parameter selection was based on the work of Allaire et al., with minor 
modifications to improve landmark selection for the lung 4DCT studies.    
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Keypoint descriptors were made of 4×4×4 subgroups each containing a 2D angular 
histogram with 8 azimuthal directions (between 0 and 360 degrees) and 4 elevation 
directions (between 0 and 180 degrees) creating a 2,048 element array. Matching a key-
point in the initial image is performed by finding a key-point in the final image that has 
the lowest Euclidian descriptor distance calculated as the distance between two 2,048 
element vectors. A pair is considered unique if the second most similar point (second 
lowest Euclidian distance) has a Euclidian distance 1.66 times larger than the most similar 
point (lowest Euclidian descriptor distance). All computation was performed on a 3.7 
GHz quad-core processor running a single-threaded program in MATLAB®. To reduce 
computation time and memory limitation, landmarking was only performed within the 
lung region. 
3.2.3 SIFT-manual hybrid 
The hybrid approach selects landmarks initially identified by the SIFT algorithm as 
previously described followed by a review of each landmark pair. Each landmark pair 
was presented to the reviewer (located in the axial plane of the image) and accepted or 
rejected based on visual similarity. The visual similarity criterion involves a quick 
evaluation of each landmark, to determine if they are both located in the same region of 
the image. An example of a rejected landmark pair is shown in Figure 3-1, where it is 
clear that the landmarks are in different slices of the image study. All landmark reviews 
were performed before any analysis took place, making the reviewer blind to true 
erroneous landmarks. 
 
Figure 3-1: Example of an excluded landmark pair (crosses) produced from SIFT. The pair was 
excluded because the landmarks were located in different slices of the CT study. 
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3.2.4 Landmark displacement evaluation 
The accuracy of each method was determined by comparison of the generated landmarks 
to the GS landmark set using two metrics: the mean (global) landmark displacement and 
proximal (local) landmark displacement.  
Mean landmark displacement was calculated as the mean displacement for all landmarks 
within a structure and was compared to the mean displacement of the gold standard 
landmark set within the same structure. Such evaluation provides a global sense of 
magnitude agreement between displacement vectors. The structures of interest were the 
left and right lungs separately, creating 20 test cases in total for all ten 4DCT studies. The 
final results were evaluated by an Intra Class Correlation (ICC) test between each 
landmarking method and the GS across all 20 lung structures. 
Proximal landmark evaluation was introduced to compare the displacement of a test 
landmark pair to the displacement of the closest GS landmark pair. To find a proximal 
landmark pair a test landmark pair is first selected, then a GS landmark pair is located that 
has the shortest Euclidian distance between their initial positions in the 0%-phase image 
study. Figure 3-2 illustrates the proximal landmark selection with GS1 being selected as 
the proximal landmark pair because of d1 < d2. Then using the deformation vector field 
produced from the DIR, the approximate magnitude of deformation for the test and 
closest GS landmark is determined. If the difference in magnitude of deformation 
(|ܦ஽ூோ ்| − |ܦ஽ூோ ଵ| from Figure 3-2) is greater than the smallest voxel dimension the test 
landmark pair is excluded. This final criterion is required to ensure that the proximal 
landmark initial positions are similar enough for direct comparison. The result is a set of 
test landmark pairs with the corresponding proximal GS landmark pairs. The landmark 
displacements in both sets were compared using an ICC. 
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Figure 3-2: Proximal landmark selection with landmarks in the 0% phase (circles) and 50% phase 
(squares) from the test (white) and gold standard (black) landmark sets including; landmark 
displacement D, DIR predicted landmark displacement DDIR, distance between 0% positions d and 
DIR error ε for a test landmark T, and two GS landmarks 1 and 2. 
3.2.5 Deformable image registration evaluation 
The DIR error was calculated by the algorithm from MIM software (version 6.5 
MIMVista) for each landmark as the Euclidian distance between the DIR predicted and 
actual positions of the landmark in the 50% phase shown as ε in Figure 3-2. The 
evaluation of DIR error was done for the manual, SIFT, SIFT-M and GS landmark sets 
using mean DIR error and proximal DIR error metrics. These two metrics were defined 
by the same method as the mean and proximal displacements but using the DIR error for 
each landmark pair (ε), instead of the landmark displacement (D). 
3.3 Results 
Both observers 1 and 2 were able to select 300 landmarks in each CT study pair (0% and 
50% phases) taking 1100 and 1700 minutes, respectively, resulting in an average 
generation time per landmark pair of 22 and 34 seconds. The SIFT algorithm produced on 
average 128 landmarks per study and the SIFT-M method produced on average 120 
landmarks per study. To normalize for different lung volumes, the number of landmarks 
per study was divided by the total lung volume determined from manual lung contours, 
resulting in landmarks per litre values are shown in Figure 3-3. The calculation time for 
SIFT was 47 minutes for all 10 studies, yielding an average time per landmark of 2.3 
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seconds. The hybrid SIFT-M method excluded on average 8 landmarks per study, with 
most rejected landmarks located in regions of distorted image contrast caused by motion 
artifacts. The landmark review by the SIFT-M method took on average 3.3±1.2 minutes 
per study, resulting in an overall average time of 4.1 seconds per landmark. 
 
Figure 3-3: Number of landmark pairs per litre located using SIFT and SIFT-M landmark creation 
methods for 10 4DCT studies. The SIFT-M method excludes some of the SIFT points using visual 
inspection. 
3.3.1 Mean displacement 
Comparison of the mean lung displacement for manual landmarks versus GS is shown in 
Figure 3-4a with an ICC value of 0.86 for both observers. The SIFT algorithm’s mean 
lung displacement is compared to the GS method in Figure 3-4b, with an ICC value of 
0.85, and the results for the SIFT-M method were similar (shown in Figure 3-4b) with an 
ICC of 0.82.   
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Figure 3-4: Mean lung deformations for 20 lungs: a) Observers 1 and 2 vs GS and b) SIFT and SIFT-
M methods vs GS. The black line shows ideal agreement. 
3.3.2 Proximal deformation 
The proximal deformation comparison between manual landmarks and GS gave an ICC 
of 0.97 and 0.98 for observer 1 and 2 respectively. When compared to the GS, the SIFT 
algorithm had an ICC value of 0.91 with the results from all ten studies presented in 
Figure 3-5a. With the removal of visually dissimilar landmarks using SIFT-M, the results 
became much more reliable (Figure 3-5b) with an ICC of 0.96.  
The summary of landmark comparisons is presented in Table 1. 
 
Figure 3-5: Landmark displacement for proximal pairs for a) SIFT vs GS and b) SIFT-M vs GS for 
all ten studies. 
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3.3.3 Deformable image registration evaluation 
For the mean DIR error (per lung) the accuracy varied significantly between manual and 
SIFT methods with ICC values of 0.97, 0.89 and 0.65 for observer 1, observer 2 and 
SIFT-M, respectively. For the proximal DIR error, the ICC values were 0.94, 0.96 and 
0.90 for observer 1, observer 2 and SIFT-M respectively. The results for DIR error and 
landmark displacement for both proximal and mean methods are shown in Table 1 along 
with the 95% confidence intervals, across both users, SIFT and SIFT-M techniques. 
Table 3-1: ICC values and corresponding 95% confidence intervals for DIR error and landmark 
displacement for both mean and proximal methods. 
  Proximal  
displacement  
Mean Lung  
displacement 
Proximal DIR 
Error  Mean DIR Error 
SIFT 0.91 (0.90-0.92) 0.84 (0.67-0.94) 0.80 (0.77-0.82) 0.72 (0.43-0.88) 
SIFT M 0.96 (0.96-0.97) 0.82 (0.61-0.93) 0.90 (0.89-0.92) 0.65 (0.30-0.84) 
Observer 1 0.97 (0.97-0.97) 0.86 (0.69-0.94) 0.94 (0.94-0.95) 0.97 (0.93-0.99) 
Observer 2 0.98 (0.98-0.98) 0.86 (0.69-0.94) 0.96(0.95-0.96) 0.89 (0.76-0.96) 
 
3.4 Discussion 
Producing a landmark set on medical image studies for the purpose of DIR evaluation is a 
laborious and tedious task that can take several hours for even the most experienced 
individual. Automatic landmarking tools are very attractive if they can provide a reliable 
set of landmarks to properly evaluate a deformation vector field produced by a 
commercial DIR algorithm. In this study, we have shown a possibility of a six-fold 
reduction in time required. With optimization using parallel computing a further reduction 
by 20 times compared with purely manual methods appears feasible. In the future, 
automatic landmark placement could make near-real-time DIR evaluation a reality, 
providing users with more confidence in the quality of their DIR, whenever it is used.  
One of the biggest issues with automatic landmarking is producing a sufficient number of 
relevant landmarks throughout the image space. In this study we limited the location of 
landmarks within the left and right lungs, obtaining 128 landmarks per study using SIFT, 
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compared to the 300 landmarks per study used in the gold standard. The number of 
landmarks per image varies drastically between images due to the difference in image 
quality as shown by the low landmark count per litre in studies #5 and #6 (Figure 3-2) 
which exhibited the worst CT image quality. 
Too few landmarks per structure can significantly alter the regional analysis of 
deformation and DIR error as demonstrated by the lower correlation between GS and 
SIFT for mean displacement and mean DIR error compared to the proximal values. This 
relatively low correlation for mean lung deformation values was also present when 
comparing GS landmark pairs to the ones selected by each observer, demonstrating that 
even 300 landmarks were not sufficient to effectively represent the overall range of 
deformation in both lungs. The distribution of landmarks can significantly affect any 
regional analysis, especially in structures exhibiting a large amount of deformation or 
points lying in high dose gradients for dose accumulation studies. Study #8 had the 
largest lung deformation and the largest discrepancy in mean lung deformation from the 
GS as shown by the largest outlier in Figure 3-4. Higher quality images allow for a more 
reliable identification (both automatically and manually) of a greater number of unique 
landmark pairs per study. For example, study #3 had superior image quality and fewer 
motion artifacts than study #6, resulting in twice as many landmarks located per litre of 
lung tissue.  
Apart from investigating global deformation properties of an entire structure, another 
important factor in deformation analysis is the accuracy of each individual landmark pair 
in describing the local deformation. Landmarks created by different methods or observers 
very rarely lie on the same point, making it practically impossible to directly compare two 
landmark pairs and their impact on evaluating a specific DIR algorithm. Currently, 
landmark evaluation is done with manual inspection of each landmark, to determine the 
mismatch [7, 4]. In this study, we proposed a new method of comparing landmarks pairs 
that are in close proximity.  Using this method to compare the landmark displacement 
between SIFT-M and the GS yielded an ICC greater than 0.95. Even with the added 
uncertainty of evaluating only proximal landmark pairs between each method and the GS, 
the reliability of the new landmark sets was maintained.  Comparison of the two sets of 
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measurements was performed using an ICC because it evaluates the relative agreement 
between two different landmarking methods. For this reason, these ICC values cannot be 
directly compared to other landmarking methods produced from other image sets, because 
they could have a different range of landmark displacements. 
Aside from the obvious efficiency benefits of automatic landmarking software, there are 
often hidden pitfalls from overlooked erroneous landmark pairs. A SIFT algorithm 
matches uniquely contrasted regions (i.e. neighbourhood pixel intensities) in image pairs, 
but it has difficulty in non-unique regions allowing occasional significant feature 
mismatch. In spite of attempts to improve the landmarks by employing several program 
iterations and setting different parameters, between 5%-7% erroneous landmarks were 
still produced per image. To discard any incorrect landmarks, a simple manual review and 
removal process was implemented, improving the ICC value of proximal displacement 
from 0.91 to 0.96, while only doubling the time per landmark generation. The manual 
review process was performed using 2D images in the axial plane which created a bias in 
the landmark selection due to anisotropy but avoided the timely task of manually 
inspecting multiple planes. Even with the added landmark review process, the SIFT-M 
method was still six times faster than a purely manual approach. 
The proximal landmark evaluation has demonstrated that the SIFT method performed 
slightly worse than the manual landmark method when compared to the GS baseline set. 
Through the quick removal of obvious erroneous landmarks using SIFT-M, the landmark 
accuracy was indistinguishable from the performance of manual users. These results 
demonstrate that semi-automatic SIFT landmarks can be used as a replacement for 
common manual landmarks in the evaluation of DIR. One important caveat is that any 
landmarking algorithm can create incorrect landmark pairs, but using a simple “sanity 
check” and ergonomic display software, these landmarks can be effectively removed 
through visual inspection. In the future, SIFT algorithms could be developed to 
incorporate further consistency checks on these landmarks to further reduce user 
involvement and correction. 
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3.5 Conclusion 
Manually selected image landmarks have long been a standard for guiding image 
registration but require a large time investment. We provide a practical evaluation method 
of automatic landmarks as a replacement for manual landmarks with a six-fold time 
reduction. The SIFT-M method was significantly faster and required only minimal post-
hoc user intervention to achieve comparable accuracy. Therefore, automatic landmarking 
methods can provide a standardized method for guiding and evaluating DIR algorithms 
without lengthy landmarking sessions. The remaining challenge for both automatic and 
manual landmarking methods is the selection of the optimal /sufficient number or spatial 
distribution of landmarks to accurately characterize the deformation of a large 
heterogeneous structure such as the lung.  
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Chapter 4 
 
4 Representing the dosimetric impact of deformable image 
registration errors 
This chapter has been previously published as “Representing the Dosimetric Impact of 
Deformable Image Registration Errors” published in the journal Physics in Medicine and 
Biology 62(17) N391 by Jason Vickress, Jerry Battista, Rob Barnett and Slav Yartsev. 
Permission to reproduce this article was provided by the publisher and presented in 
Appendix A.4. 
4.1 Introduction 
Deformable image registration (DIR) is becoming a common tool for all image-guided 
procedures including radiation therapy, making it possible to track changes in a patient’s 
anatomy using longitudinal image studies. Cumulative dose calculation across multiple 
fractions has been introduced for a number of treatment sites including cervical [1-3] and 
prostate [4] cancer.  The result of a DIR is a deformation vector field (DVF) which maps 
every point between pairs of images and may be used to accumulate dose in a reference 
image. The veracity of DIR dose accumulation depends on the accuracy of the DVF, 
translating registration errors to potentially significant errors in dose.  
Improvements in radiation delivery techniques allow for highly conformal treatments 
with steep dose gradients. While high dose gradients are attractive to improve patient 
outcomes, they may amplify DIR errors into large dose errors. Many vendors of treatment 
planning software have produced their own unique algorithms each functioning with 
different similarity metrics and regularizers. A range of different DIR results was 
demonstrated using 12 algorithms on a deformable pelvic phantom [5] and two 
algorithms using a head and neck phantom [6]. Other studies have quantified the DIR 
error of various commercial products [7, 8]. 
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One way of visualizing the impact of DIR error is via the addition of error bounds to a 
planned dose volume histogram (DVH) curve, as proposed by Risholm et al. [9] using a 
probabilistic registration to account for the DIR uncertainty. From the literature, the 
common evaluation of DIR error for commercial algorithms was done by reporting an 
expected global DIR error [10-12]. However, clinically it is more important to evaluate 
the local dose uncertainty from the DIR error at each point in the image.  
Currently, landmarks serve to match point pairs and constitute the most effective method 
of local DIR evaluation, measuring the registration error at individual sample voxels 
within an image volume. Such landmarks are useful for determining the dosimetric 
impact at single voxels, but cannot be used for evaluating the dosimetric impact 
throughout an entire image volume since they are limited to a discrete set of voxels. To 
fill this role several methods have been developed to predict DIR error in every point of 
an image volume, allowing the evaluation of the specific DVF used for dose 
accumulation [13-15]. 
In this study, a set of well-defined landmarked image pairs were used to characterize DIR 
error at multiple voxels, with the aim of exploring its dosimetric impact. With the 
dosimetric impact determined at each landmark as the gold standard, the effectiveness of 
different measures of DIR error can be evaluated and if found promising propagated to 
the entire volume. To the best of our knowledge, this is the first study to investigate the 
impact of DIR uncertainty on dosimetric analysis using landmarks as reference data. 
4.2 Methods 
4.2.1 4DCT studies and deformable image registration 
Ten thoracic 4DCT images with standardized landmarks were obtained from “dir-lab” 
(www.dir-lab.com) [16] and 300 landmarks were provided for each image study pair 
matching the end-inspiration and end-expiration phases, matching every point in the end-
inspiration study with a corresponding point in the end-expiration study. Landmarks were 
located across both the left and right lung with no significant bias and were not limited to 
only the clinically important regions within the lung.  All images were reconstructed 
axially with an in-plane resolution between 0.97 mm and 1.16 mm with a matrix size of 
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256 × 256 (5 studies) and 512 × 512 (5 studies) and common slice thickness of 2.5 mm. 
Actual DIR error was calculated for each landmark pair by calculating the Euclidian 
distance between the DIR predicted landmark position in the end-expiration phase and the 
actual landmark position. Mean DIR error per study was calculated as the average 
landmark error of all 300 landmarks per study. In this work, all DIR procedures were 
performed using the standard DIR algorithm within the MIM Maestro software package 
(version 6.5 MIM, MIM Software Inc, Cleveland, OH, USA) with no additional refining 
of the DVF. Dose distributions were planned on the inspiration phase of each 4DCT study 
with standard five-field IMRT plans of a 60 Gy prescription dose to 95% of the planning 
target volume (PTV) with maximum doses ranging 69-73 Gy. Each study had a single 
target (no nodes) with gross tumour volumes (no ITV) ranging 1 – 43 cm3, with 5 located 
in the upper left lobe, 3 in lower left lobe and 2 in the lower right lobe. All dose 
calculations were performed on both inspiration and expiration phases using the plan 
from the inspiration phase using Pinnacle treatment planning system software version 
9.10 (Philips Healthcare, Fitchburg, WI, USA). 
4.2.2 DIR error prediction 
We investigated three DIR error prediction methods: inverse consistency error (ICE), 
transitivity error (TE) and the distance discordance metric (DDM). Each method 
produced a value (pm) in millimetres proportional to the DIR error (DE) using the actual 
landmark displacement error as the gold standard. DE was calculated by Eq. (1), where k 
is the slope and C is a constant (in millimetres) found by the linear regression of the data 
from each prediction method vs actual DIR error for all 3000 landmarks in the collection 
of ten 4DCT image studies. 
ܦܧ = ݌݉ × ݇ + ܥ                           (1) 
4.2.2.1 Inverse consistency error 
The ICE is calculated as the disagreement between the forward and backward DVFs 
between the end-inspiration (0%) and end-expiration (50%) phase studies. Calculation of 
ICE was done with equation 2 and 3, with the coordinates in the 0% as (x,y,z) and the 
forward and backward DVFs as DVF0-50 and DVF50-0 respectively.  
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(ݔூ ,ݕூ , ݖூ) = (ݔ, ݕ, ݖ) + ܦܸܨ଴ିହ଴(ݔ,ݕ, ݖ) + ܦܸܨହ଴ି଴൫(ݔ,ݕ, ݖ) + ܦܸܨ଴ିହ଴(ݔ, ݕ, ݖ)൯ (2) 
ܫܥܧ = ඥ(ݔூ − ݔ)ଶ + (ݕூ − ݕ)ଶ + (ݖூ − ݖ)ଶ             (3) 
 
4.2.2.2 Transitivity error 
The TE is calculated in a similar manner to the ICE but includes the disagreement 
between three DVF’s across three different image studies (the 0%, 30% and 50% image 
studies). Calculation of TE was done with equation 4 and 5 with DVF0-30 and DVF30-50 
denoting the DVF’s between the 0% and 30%, and 30% and 50% respectively. (ݔ′,ݕ′, ݖ′) = (ݔ, ݕ, ݖ) + ܦܸܨ଴ିଷ଴(ݔ,ݕ, ݖ) + ܦܸܨଷ଴ିହ଴൫(ݔ, ݕ, ݖ) + ܦܸܨ଴ିଷ଴(ݔ,ݕ, ݖ)൯    (4) (ݔ்,ݕ் , ݖ்) = (ݔᇱ, ݕᇱ, ݖ′) + ܦܸܨହ଴ି଴(ݔ′,ݕ′, ݖ′)                 (5) 
ܶܧ = ඥ(ݔ் − ݔ)ଶ + (ݕ் − ݕ)ଶ + (ݖ் − ݖ)ଶ                                            (6) 
4.2.2.3 Distance discordance metric 
The DDM is a simplified version from Saleh et al. [14] using ten phases (0, 10, 20, 30, 
40, 50, 60, 70, 80 and 90%) of the 4DCT images to evaluate the DVF between the 0% 
and 50% phase. Calculation is performed using equations 7 and 8 shown below where Pi 
is one of the 8 additional phases (10, 20, 30, 40, 60, 70, 80, 90%) and (x0-50, y0-50, z0-50) is 
the position in the 50% from the 0% phase using the DVF0-50. (ݔ௜,ݕ௜ , ݖ௜) = (ݔ, ݕ, ݖ) + ܦܸܨ଴ି௉೔(ݔ, ݕ, ݖ) + ܦܸܨ௉೔ିହ଴ ቀ(ݔ, ݕ, ݖ) + ܦܸܨ଴ି௉೔(ݔ, ݕ, ݖ)ቁ    (7) 
ܦܦܯ = ଵ
଼
∑ ඥ(ݔ௜ − ݔ଴ିହ଴)ଶ + (ݕ௜ − ݕ଴ିହ଴)ଶ + (ݖ௜ − ݖ଴ିହ଴)ଶ଼௜             (8) 
4.2.3 The range of dose uncertainty 
The range of dose uncertainty (RDU) was calculated for each individual landmark in the 
end-inspiration phase as a function of the DIR error and the dose distribution calculated 
on the end-expiration phase study. A flowchart describing the process of calculating the 
RDU is shown in Figure 4-1, with a corresponding illustration in Figure 4-2. The first 
step used the DVF to find the DIR-predicted location of the landmark in the end-
expiration phase of the image by adding the corresponding deformation vector to the 
initial landmark position in the end-inspiration phase. A sphere of surrounding voxels was 
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created around the predicted landmark position in the end-expiration phase, with the 
sphere’s radius equal to one of the measures of DIR error for that landmark (2D 
illustration in Figure 4-2). Multiple measures of DIR error included (i) the actual DIR 
error, (ii) the mean DIR error per study, (iii) ICE, (iv) TE, (v) DDM prediction methods, 
(vi) 2 mm, and (vii) 5 mm constant values (representing low and high errors from the 
average error of 3.5 ±5.5mm). A spherical sampling volume was created from an 
11×11×11 voxel cube with the exclusion of voxels with r > (1.1 × side-length/2). To 
accommodate a sphere with a radius equal to the measure of DIR error the cube’s side 
length was set at twice this measure. The result is an approximate sampling sphere of 739 
voxels with an approximate radius equal to the measure of DIR error. 11×11×11 
dimension was selected as a reasonable compromise between a representative number of 
voxels and limitations of memory consumption and computation time. A histogram of 
dose values throughout the sphere shown in Figure 4-2c was calculated using linear 
interpolation from the dose grid values. The RDU in this sphere was defined by the 
maximum and minimum dose values within the dose voxel histogram. The RDU was 
designed to evaluate the possible doses given the limits of known registration error. The 
RDU calculated using the actual DIR error as the radius of the sampling sphere 
characterizes the true dose uncertainty which is used to compare with other estimation. 
 
Figure 4-1: Flowchart outlining the calculation of the range of dose uncertainty for a single landmark 
starting in the end-inspiration image. 
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Figure 4-2: RDU process for a single landmark in end-inspiration phase. The DIR predicted position 
of the landmark is located in end-expiration image and dose is sampled in a sphere around it. RDU is 
the maximum and minimum doses within the sampling sphere a) end inspiration b) end respiration c) 
dose voxel histogram for points within the sampling sphere. 
4.2.4 Dose uncertainty evaluation 
Evaluation of the calculated dose uncertainty was performed using two methods: the 
magnitude of dose uncertainty (MDU) and the inclusion rate (IR). The MDU is simply 
the size of the RDU in units of Gy. The MDU was calculated for each individual 
landmark in the end-inspiration phase and averaged over all 3000 landmarks across all ten 
4DCT studies. Another important characteristic is determining if the actual dose value 
lies within the RDU. For an individual study (containing 300 landmarks) the IR is the 
percent of landmarks where the actual dose value lies within the RDU “error bars”. The 
IR was calculated for each individual study and averaged over all 10 studies. The 
sensitivity of the proposed methods was tested using a total of 3000 unique landmarks 
experiencing various ranges of deformation error within different local dose distributions. 
Both the MDU and IR were calculated for RDUs using each measure of DIR error (actual 
DIR error, mean actual DIR error per study, 2 and 5 mm, ICE, TE and DDM). 
Comparisons between different methods MDU and IR values were performed using a 
two-tailed paired T-tests for a significance level below 0.05 for IR since it was calculated 
for each study and averaged, and below 0.01 for MDU because it was averaged across all 
3000 landmarks. 
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4.2.5 Dose uncertainty distribution 
The uncertainty of a deformed dose distribution was produced by calculating the RDU at 
each voxel using a given initial dose distribution and DVF derived from MIM Maestro. 
Unlike calculating the RDU at specific landmarks, calculating it at every voxel within a 
volume requires an estimation of registration uncertainty for each voxel performed with 
DDM.  The RDU at each voxel is defined by two values: the upper and lower bounds of 
the deformed dose. The deformed dose distribution is where every voxel in the end-
inspiration study is mapped to a dose value from the dose distribution calculated on the 
end-expiration study. Calculating the RDU at every voxel in the end-inspiration study 
creates two dose distributions for the upper and lower bounds of the deformed dose 
distribution representing all possible levels of dosimetric impact.  Visualization of the 
dose uncertainty distribution was done by displaying the two dose distributions for the 
upper and lower bounds of the deformed dose.  Cumulative DVHs for the PTV were 
computed for the planned dose and deformed dose containing the upper and lower 
bounds. 
4.3 Results 
4.3.1 DIR error prediction 
Linear regression was performed for each DIR prediction method (ICE, TE and DDM) vs 
the actual DIR error. Linear regression factors for the DDM method were k = 2.05 (2.02-
2.08) and C = 1.10 (1.01-1.18) mm with a Pearson correlation of R2 = 0.71 (p < 0.001), 
for the ICE method k = 0.79 (0.76-0.82), C = 1.86 (1.73 – 1.99) mm and R2 = 0.34 (p < 
0.001), and for the TE method k = 0.81 (0.77-0.84), C = 1.76 (1.64-1.89) mm and R2 = 
0.37 (p < 0.001). 
4.3.2 The range of dose uncertainty 
The RDU was calculated for 300 landmarks from the end-inspiration phase on each of the 
ten 4DCT images. The results for 31 landmarks receiving the largest radiation dose (from 
a single study) are shown in Figure 4-3 using a constant error of 2 mm and 5 mm, the 
DDM, and the actual DIR error. For a constant error of 2 mm (Figure 4-3a), the RDU 
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values encompass the actual dose value 71% of the time (i.e. the inclusion rate for this 
subset of 31 landmarks) because the ranges are not large enough. A 5 mm constant error 
(Figure 4-3b) had ranges that were too large because it more frequently overestimated the 
dosimetric error than using the constant error of 2mm. For the DDM (Figure 4-3c) the 
RDU is more accurate than using 2 and 5 mm errors but not as accurate as using the 
actual DIR error (Figure 4-3d). 
 
Figure 4-3: The range of dose uncertainty (RDU) for 31 landmarks with the highest doses from a 
representative study calculated using four different measures of DIR error a) 2mm constant b) 5 mm 
constant c) DDM d) Actual error.  Actual dose (red X) and RDU is shown as a black error bar. 
Landmarks are ordered in increasing predicted dose difference from the actual dose. Dose values are 
displayed relative to the DIR deformed dose value for each landmark. 
4.3.3 Dose uncertainty evaluation 
The RDU was evaluated for 3000 landmarks in 10 studies and the average results for 
seven prediction methods are shown in Figures 4-4 and 4-5 for the MDU and IR, 
respectively.  Using the actual DIR error produced the highest average IR of 97%, while 
its average MDU value of 2.5 Gy was similar to that of the DDM, ICE and TE methods 
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which were 2.49, 2.56, 2.56 Gy, respectively, and the difference was not statistically 
significant (p > 0.01). The IR of DDM, ICE and TE were all significantly lower than 
using the actual DIR error (p < 0.05) but similar to each other (p > 0.05) with values 86, 
88, 86%, respectively. The 2 mm constant error produced the smallest IR of 75% because 
it underestimates the DIR error. The 5 mm constant error has the highest average MDU of 
3.5 Gy because it overestimates the DIR error the most. MDU’s from DDM, ICE, TE and 
mean error was significantly lower than using a constant 5 mm (p < 0.01). IR using 
constant 2 mm was significantly lower (p < 0.05) than those obtained by DDM, ICE and 
TE methods. IR for the mean error per study was significantly lower (p < 0.05) than those 
resulting from DDM and ICE methods. 
  
Figure 4-4: Magnitude of dose uncertainty (MDU) averaged across all 3000 landmarks within 10 
4DCT image studies, using the actual DIR error, 2 and 5 mm constant error, distance discordance 
metric (DDM), inverse consistency error (ICE), transitivity error (TE), and the mean actual DIR 
error per image.  Error bars represent the standard deviation across 3000 landmarks. 
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Figure 4-5: Inclusion rate (IR) averaged across all 10 4DCT image studies, using the actual DIR 
error, 2 and 5 mm constant error, distance discordance metric (DDM),  inverse consistency error 
(ICE), transitivity error (TE), and the mean actual DIR error per image.  Error bars represent 
standard deviation across 10 studies. 
4.3.4 Dose uncertainty distribution 
The dose uncertainty distributions are illustrated in Figure 4-6 for a representative study 
using the DDM as the measure of DIR error. Both the upper and lower bounds of the 
RDU have worse coverage than the planned dose distribution. The cumulative DVH 
curves of the PTV for the deformed dose with the RDU and the planned dose are shown 
in Figure 4-7 showing the degradation in target coverage. 
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Figure 4-6: Distributions, of the (a) planned, (b) deformed dose, (c) lower bound, (d) upper bound of 
the range of dose uncertainty calculated using DDM. Contour labels: (light blue) PTV and (dark 
blue) is gross target volume. Dose prescription was 60 Gy to 95% of the PTV. 
 
Figure 4-7: Cumulative DVH curves for the planned and deformed dose with the upper and lower 
bounds illustrating the range of dose uncertainty(RDU) calculated using the DDM. Dose prescription 
was 60 Gy to 95% of the PTV. 
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4.4 Discussion 
DIR accuracy can have a large potential impact on evaluations of radiotherapy treatments 
because the dose cumulates across multiple fractions introducing significant anatomical 
changes. Unlike other applications of DIR, radiotherapy dose accumulation is performed 
at the individual voxel level and errors in DIR can lead to untreated cancer or over-
irradiated sensitive tissue. Earlier studies of DIR in radiotherapy investigated contour 
propagation and dose accumulation. For contour propagation the global accuracy of the 
DIR was evaluated, focusing on the ability to define contour edges typically measured 
with a DICE coefficient. Kumarosiri et al. evaluated multiple DIR algorithms for 
propagating contours for Head and Neck cancer using the DICE coefficient [17]. While 
contour propagation is a very useful tool for IGRT, it fails to evaluate a DIR throughout 
the interior (and exterior) of the contoured region. Studies presenting dose accumulation 
applications are useful in demonstrating the potential of DIR in radiotherapy but fail at 
providing the ground truth and range of uncertainty.  Abe et al. showed the difference in 
DVH parameters using DIR compared to simple DVH parameter addition [18] to 
demonstrate benefits of using deformed dose accumulation.  
Several studies have compared the results of dose accumulation from different DIR 
algorithms [19, 20] revealing that the results are dependent on the specific DIR algorithm. 
Typically the investigation of DIR performance and uncertainty is undermined by the lack 
of ground truth. In many publications (including an earlier work by Risholm et al. [21]) 
colour maps and graphs are used to demonstrate the potential DIR uncertainty but do not 
consider the actual DIR error. Li et al. used landmarks for the direct correlation between 
a registration evaluation method and the actual DIR error but did not consider the dose 
implications [22]. Following their approach, we used landmarks to obtain the true DIR 
error and impact on dosimetric analysis, across multiple sets of image studies. Though 
this does limit the analysis to specific regions of the image, it could also be used with 
automatic landmarking software (23, 24) to provide real-time evaluation of DIR 
uncertainty. We previously showed the efficacy of using the scale-invariant feature 
transform for landmark generation in DIR evaluation and demonstrated that such 
landmarks can be a good surrogate for manually selected landmarks [25].  
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Error bounds are typically used to demonstrate the level of uncertainty for any measured 
or computed value with known limitations or from a sample with a defined statistical 
distribution. In this study, we investigated error bars representing the RDU at individual 
landmarks using different DIR error prediction methods. The RDU error bars are a 
function of both the DIR uncertainty and the local gradient of the dose distribution. For 
example, a landmark with large DIR error in a homogenous region of the dose 
distribution will have a very low MDU. In Figure 4-2b, the RDU varies greatly even 
when using a constant DIR error of 5 mm, because the dose gradient varies greatly 
throughout the image volume. The large range in RDU values is the result of using the 
maximum and minimum values from each sampling sphere. The extreme values were 
selected instead of other descriptors (i.e. 5th and 95th percentile) because it yielded the 
highest IR. The MDU and IR metrics were introduced to represent the two most 
important properties of an error bar: its size and if a “true” value lies within its bounds. 
The ideal RDU would be as small as possible minimizing MDU, while always containing 
the true value with an IR = 100%.  The RDU calculated from the actual DIR error was 
considered the gold standard representing the true dose uncertainty, with the highest IR 
while maintaining a minimum MDU. The IR while using the actual DIR error was below 
100% because of the limitations in the interpolation of dose values near the boundary of 
the sampling sphere. We evaluated different DIR prediction methods on their capability 
to represent the RDU. 
Testing the impact of DIR error for a number of test voxels is limited to regions where the 
landmarks are located and those locations may not be in clinically relevant regions. 
Determining the impact of DIR error in all parts of the image would require a method to 
quantify or predict DIR error for every point of the image volume. Several studies created 
different tools to predict the magnitude of DIR error given specific properties of the 
image volume and its deformation [13-15]. In our study, we selected the DDM for DIR 
error prediction because it could be tested with 4DCT image studies, considering each of 
the 10 phases as separate studies. The other voxel-wise predictors of DIR error (ICE and 
TE) performed similarly to DDM with differences in IR of less than 1% and differences 
in MDU within 0.1 Gy. The small differences in RDU performance were remarkable 
given that DDM had the best correlation with actual DIR error having a Pearson 
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correlation coefficient of 0.71 compared to 0.34 for ICE and 0.37 for TE. This remarkable 
result is caused by the MDU’s and IR’s insensitivity to small differences in registration 
errors produced by different measures because they present the average values across 
3000 landmarks with different local dose distributions, whereas the correlation compares 
individual landmark errors. The RDU created using the DDM was comparable to the 
RDU created using the actual DIR error defined by landmarks. The results using DDM 
were also significantly better than the RDU derived from constant error values of 2 and 5 
mm having a significantly higher IR and lower MDU respectively. Even the mean DIR 
error for each study performed worse than the DDM demonstrating that the 
heterogeneous distribution of DIR error throughout a lung volume makes global measures 
of DIR error inadequate and should be avoided for this application. 
Presently commercial DIR software is being used to calculate the cumulative dose 
distributions without considering the impact of registration uncertainty on the risks 
associated with poorer tumour control, increased toxicities, and long-term cancer. 
Currently in radiation therapy many uncertainties in the treatment planning, delivery and 
alignment are accounted for when developing a patient’s treatment plan, but DIR 
uncertainty is normally neither included nor propagated across dose fractions. Ideally, the 
dose uncertainty should be defined as the dose between the DIR predicted and reality, but 
without landmarks located throughout the image space, this is not feasible. Utilizing 
different measures of DIR error such as DDM allowed the calculation of a range of 
potential dose error throughout the whole volume. By taking the maximum and minimum 
dose values within the sphere, the method quantifies the most conservative situation when 
the registration error is always in the direction of the largest dose difference. Such 
information is valuable for the radiation oncologist by indicating possible areas of 
concern. In radiation therapy practice the knowledge of the RDU provides information on 
the span of possible dose values, indicates the reliability of the applied DIR algorithm and 
can prompt further investigation, including contouring or further imaging. The RDU 
evaluation proposed in this work can be included to account for DIR uncertainty limits 
when applied to dose accumulations, and allow DIR based dose accumulation to become 
standard in radiotherapy clinics. Our future work plans to apply the RDU approach to 
other cancer sites using clinical treatment plans to demonstrate how it can impact real 
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treatment decisions.  The goal is to introduce the RDU evaluation so that it becomes 
commonplace whenever DIR is used to assess the impact on a cumulative radiation dose 
distribution. 
4.5 Conclusion 
DIR error is inevitable for any application of repeated image guidance that requires 
highly accurate DVF solutions. In our study, we determined the impact of DIR error on 
the dosimetric analysis and found that surrogates of DIR uncertainty can provide error 
bars for the cumulative dose distribution. Using the landmarks actual displacement error 
as the gold standard we evaluated the dose-predictive power of various measures of DIR 
error. The RDU evaluation was developed to represent the range in the deformed dose 
distribution. Calculation of the RDU required a measure of DIR error and it was shown 
that voxel-wise predictions of DIR error (such as DDM) performed best, second only to 
using the actual DIR error. It was also confirmed that fixed global measures of DIR errors 
are not adequate for determining the RDU when compared to voxel-wise methods. The 
RDU calculated using the DDM provided the upper and lower dose limits throughout an 
entire deformed dose distribution, not being limited to specific landmarks. Ultimately the 
RDU can provide a useful representation of the dosimetric impact of registration 
uncertainty for any commercial DIR algorithm, providing clinicians with a more realistic 
analysis of how accurately a radiation treatment is converging to the prescribed treatment. 
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Chapter 5 
 
5 Online daily assessment of dose change in head and neck 
radiotherapy without dose-recalculation 
This chapter has been accepted for publication in the Journal of Applied Clinical Medical 
Physics By Jason Vickress, Jerry Battista, Rob Barnett and Slav Yartsev. The article will 
be open access.  
5.1 Introduction 
Radiation therapy is a standard treatment option for a variety of cancers where the precise 
geometric targeting of tumours can be exploited for achieving better tumour control while 
limiting healthy tissue damage. The specific targeting and attenuation of radiation are 
unique to the patient’s anatomy at the time of the planning-CT simulation (PCT), but 
these conditions are difficult to maintain throughout an entire course of treatment due to 
changes in anatomy [1-4]. To account for changes in patient anatomy, plan modification 
may be required during the treatment course to ensure accurate targeting. Plan adaptation 
has been shown to improve treatment outcomes by promoting better tumour control and 
limiting toxicities [5, 6], but this procedure entails additional costs of re-imaging, re-
planning, and additional quality assurance. Though the potential benefits of plan 
adaptation are obvious, no guidelines on decision-making and optimal time for re-
planning are available. 
Plan adaptation has been reported for various treatment sites including lung [7], prostate 
[8-10], and head and neck cancers [11, 12]. Across all treatment sites, adaptation is 
necessary due to tumour shrinkage, weight loss or other significant anatomical changes 
that impact the dose distribution (e.g. lung collapse or re-inflation).  Specifically for head 
and neck cancers, large volume changes are common and often detected by external 
examination or through poor fitting of immobilization devices, but minor changes can go 
unnoticed. However, relatively minor anatomy changes may still have a significant effect 
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on the dose distribution and are more difficult to discern by visual inspection of anatomy 
alone. 
More precise and conformal radiation treatments available with modern techniques may 
need more plan adaptations to provide consistent target dose coverage and healthy tissue 
sparing with a changing anatomy. For making a decision on the necessity of plan 
adaptation in clinical practice, efficient daily evaluation of the delivered dose distribution 
on the modified anatomy is required. Different methods have been presented on detecting 
volume changes [13] and landmark movements [14] but most rely solely on visual 
inspection by clinicians. These visual inspections may not be consistent as shown by 
inter-observer studies [15]. Several groups have presented adaptation strategies and 
schedules throughout treatment [16, 17]. A recent study using the same dataset as in this 
study has produced a method of detecting anatomical differences to flag consideration of 
plan re-evaluation without considering the dose distribution [18]. 
Currently, cone beam CT (CBCT) imaging is routinely used for patient alignment and 
anatomy monitoring but can also be used for dosimetric assessment of actual radiation 
delivery.  Dose calculations on CBCTs are possible with the results varying between 
reported studies [19-21] because of inferior image quality and tissue densitometry. 
Performing reliable analysis of the dose to the target and organs at risk would require 
contouring of relevant structures on the daily CBCT image. An attractive alternative is to 
employ deformable image registration (DIR) to transfer contour information from the 
planning CT study for analysis.  DIR has been shown to produce a variety of results 
depending on the algorithm used, original contouring accuracy and imaging modalities 
(i.e. CT simulation, MRI or CBCT). Unfortunately, registration between different 
imaging modalities has been shown to have worse accuracy [22] especially for CBCT 
images due to limited image quality and artifacts.  
There are two primary effects of anatomical deformations on a radiation treatment: 1) 
movement of voxels and regions on interest (ROI) relative to the planned dose 
distribution and 2) change of the dose distribution itself due to re-arrangement of voxels 
or density changes therein. The current gold standard (GS) for determining whether to 
adapt a treatment plan involves a new CT simulation (ReCT), dose calculation and DIR to 
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map contours from the PCT. This procedure is time-consuming and expensive but 
accounts for both effects of anatomical deformation and is applied when gross anatomical 
changes are suspected.  
The best alternative without a new CT simulation involves using DIR to warp the 
planning CT to match the daily anatomy from the CBCT and perform dose calculation as 
proposed by Veiga et al [23] and accounts for both effects of anatomical deformations. 
However, the dose recalculation practically can be difficult and time-consuming. It is 
usually performed off-line which limits its routine daily use at the treatment unit. What if 
you could determine the necessity of plan adaptation without a new CT scan and dose 
calculation? Without the re-computation of the dose, only the movement of voxels and 
ROI’s relative to the planned dose distribution are considered, but not the change to the 
dose distribution. The dose distribution is assumed to be robust and only mildly affected 
by the re-arrangement of the voxels.  In this study, we explore the results of using the 
CBCT without a dose calculation and a CBCT with a dose calculation and compare both 
to the current gold standard. The goal is to see if assessing the movement of ROI relative 
to the planned dose distribution provides enough dose information to properly trigger the 
plan adaptation process, when compared to current clinical practice of visual inspection.   
5.2 Methods 
5.2.1 Patient studies 
 For this study, 18 patients who received multi-fractionated radiotherapy for head-
and-neck cancer and had plan adaptation during treatment course were selected. Each 
patient had a CT scan taken before treatment (range 4-30 days) and used for planning (i.e. 
PCT), daily pre-treatment CBCT studies and another CT re-taken during treatment 
(ReCT) when anatomy changes were deemed significant (day “X”). Significant changes 
included sensitive structures moving into high dose regions, tumour moving out of this 
region or excessive weight loss by the patient. Both PCT and ReCT studies were obtained 
on a 120 keV Phillips Big Bore CT scanner (Philips Healthcare, Fitchburg, WI, USA) 
with a 512 x 512 image size, 0.9-1.2 mm resolution, and 3 mm slice thickness. CBCT 
scans were performed every 1 to 5 fractions with the onboard imaging available on 
Varian iX and True Beam treatment units (Varian Medical Systems, Palo Alto, CA, USA) 
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using 100 keV with a 512 x 512 or 384 x 384 image size, 0.5 – 0.65 mm resolution and 
2.5 – 2 mm slice thickness. Treatment plans had prescribed doses ranging 50-70 Gy to the 
planning target volume (PTV) in 30 to 35 fractions using volumetric arc therapy (VMAT) 
with two 360◦ arcs and included 1 or 2 target volumes. Specifically, 15 patients had only 
one target, 3 had two targets and all patients had a larger nodal volume overlapping all 
targets prescribed to a lower dose. Treatment planning and dose calculations were 
performed on a Pinnacle treatment planning system (version 9.10, Philips Healthcare, 
Fitchburg, WI, USA) using Pinnacle’s collapsed cone convolution superposition 
algorithm [24] using a dose grid of 3×3×3 mm. All image registrations (both rigid and 
deformable) were performed with software from MIM Maestro (version 6.5 MIM 
Software Inc., Cleveland, OH, USA) using the default DIR algorithm applying an 
intensity based free form algorithm, with a sum of squared differences similarity metric 
[25]. The mean registration error using MIM Maestro between two kVCT’s was shown to 
be 1.7 mm by Kirby et al. [22] using a deformable Head and Neck phantom. 
5.2.2 Dose distribution estimation 
To determine the necessity of plan adaptation, an estimation of the dose distribution “of 
the day” was required and three estimation methods are presented and compared to the 
current gold standard which requires a re-planning CT. The first method (CBCTP) used 
DIR to map the contours from the PCT to the daily CBCT with the planned dose 
distribution rigidly registered to the daily CBCT as shown in figure 1.  
 
Figure 5-1: Illustration of the CBCTP method for the evaluation of the need for plan adaptation using 
the DIR of planning CT to daily CBCT study and the planned dose distribution. DIR – deformable 
image registration, RR – rigid registration. 
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The second method (CBCTR) used the DIR to map the contours from the PCT to the daily 
CBCT with the recalculated dose (from the ReCT) rigidly registered to the daily CBCT. 
The third method (ReCTP) used the DIR to map the contours from planning CT to the 
ReCT with the planned dose distribution rigidly registered to the ReCT. The gold 
standard method (ReCTR) applied DIR to map contours from the PCT to ReCT with the 
recalculated dose on the ReCT. Both dose distributions (planned and recalculated) were 
obtained using the original treatment plan parameters and beam; the plan was not re-
optimized. The rigid registration process used 6 degrees of freedom and simulated the 
alignment of the CBCT study to PCT (or ReCT) performed by the radiation therapists in 
the clinic before each fraction. In total, four separate methods estimated the daily dose 
distribution using the CBCT or ReCT as the secondary CT study, with the planned or 
recomputed dose. For clarity, each method was referred to by the secondary image used 
(CBCT or ReCT) and if the planned or ReCT dose was used, denoted by subscript P or R, 
respectively. All dose estimation methods are illustrated in figure 2, showing all four 
investigated combinations.  
 
Figure 5-2: Schema describing the daily dose estimation using DIR from the planning CT to either 
the daily CBCT or re CT study (ReCT). Two different dose distributions computed on the PCT or 
ReCT are transferred to the moving image using a 6 degree of freedom rigid registration. The gold 
standard method is highlighted in yellow using the ReCT and recomputed dose. Day X is when ReCT 
was ordered due to observed significant anatomical changes. 
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5.2.3 Voxel-to-voxel dose comparison 
The clinically relevant comparison of the dose results obtained by different estimations 
requires evaluation on a voxel-to-voxel basis. Every voxel in the PCT study can have a 
different dose value in fraction X (when ReCT was ordered), depending on the secondary 
CT study for image registration and the dose distribution. Comparison with any other 
method is done by calculating the relative dose difference to the GS (RDj) for a specific 
structure j across each individual voxel i: 
ܴܦ௝ = ଵଵ଼∑ ଵேೕ ∑ ቚ஽(ீௌ)೔೛ೕ ି஽(்)೔೛ೕ ቚ஽(ீௌ)೔೛ೕ × 100%ேೕ௜ଵ଼௣                (1) 
between a test method (T) and GS averaged over all Nj voxels within all 18 patients p.   
Voxel-to-voxel analysis was performed for the right and left parotids because they were 
present in all image studies, incurred significant deformation and are frequently 
positioned close to the target volume. The analysis was also performed for the spinal cord 
because it is a clinically important structure.  
5.2.4 Test for the necessity of adaptation  
In practice, the estimations of dose distribution changes would be used to determine if a 
current plan delivery is not within clinical dose tolerances and needs adaptation. For our 
dose distribution estimation methods, adaptations were considered necessary if the 
following dose tolerances were exceeded: mean dose to parotid equal or above to 26 Gy, 
max dose to spinal cord equal or above 50 Gy or dose to 95% of the PTV below the 
prescription dose. Using two of the methods, CBCTP and CBCTR, dose values were 
calculated and compared to clinical tolerances to see which method would accurately 
trigger plan adaptation, when compared to the gold standard (ReCTR). Any parotid with a 
planned mean dose equal or above 26 Gy was excluded from this test since the organ was 
already planned to receive greater than the tolerated dose. The spinal cord is an important 
organ for head and neck radiotherapy planning, but was not considered for the necessity 
of adaptation test since the threshold for a max dose of 50 Gy was only crossed by one 
patient.  
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For the PTV the dose was determined at each voxel using CBCTP and CBCTR methods. 
The threshold criterion for adaptation was for 95% of the volume (D95) to be below the 
prescribed dose. The D95 parameters were selected because following recommendations 
for evaluating the target coverage [26]. Only the primary PTV was analyzed for each 
patient. 
Evaluation of the clinical decision to adapt or not relied on the compliance with both 
parameters: the parotid mean dose and D95 to the PTV. To simulate a conservative 
treatment situation the mean parotid dose and max spinal cord dose was rounded to the 
nearest integer, for example, 25.6 Gy is rounded to 26 Gy. The results were reported as 
the number of unnecessary adaptations (adapting, when within tolerance) and missed 
adaptations (not adapting, when tolerances were exceeded). 
5.3 Results 
5.3.1 Voxel-wise dose comparison 
The relative dose difference RDj given by equation (1) for each method are shown in 
table 1 for the ipsilateral and contralateral parotids and spinal cord. The error caused by 
only the changed dose distribution is presented by the ReCTP row and the CBCTR row 
represents the error caused only by the DIR between different imaging modalities. CBCTP 
row represents the error when both effects were present. 
Table 5-1: Relative voxel-wise dose difference from gold standard (ReCTR) (RDj) for ipsilateral and 
contralateral parotids and spinal cord, averaged over 18 patients. Standard deviation is displayed in 
brackets. 
Secondary image and  
dose distribution Ipsilateral Parotid 
Contralateral 
Parotid Spinal cord 
ReCTP 8 % (5.7 %) 7.9 % (5 %) 3.8 % (1.6 %) 
CBCTP 12.7 % (9.5 %) 13.5 % (7.8 %) 5.7 % (2.4 %) 
CBCTR 7.5 % (4 %) 7.7 % (4.5 %) 4 % (2 %) 
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5.3.2 Test for the necessity of adaptation  
The parotid mean dose estimates using CBCTP and CBCTR are compared relative to the 
26 Gy threshold to the gold standard (ReCTR) in figures 3a and 3b, respectively.  The 
number of parotids that were incorrectly labelled as either greater than or less than 26 Gy, 
out of 15 tested parotids was five for CBCTP and one for CBCTR. The D95 estimates 
relative to the dose prescription for CBCTP and CBCTR are compared to the gold standard 
in figures 4a and 4b, respectively. The number of patients where the CBCT-based 
prediction was different from the gold standard on their PTV D95 parameter (out of 18 
patients) was one for both CBCTP and CBCTR. 
 
Figure 5-3: Predicted mean dose using a) CBCTP and b) CBCTR methods compared to ReCTR (gold 
standard) for 15 parotid glands. Clinical threshold of 26 Gy is shown by solid lines. ReCTR is the DIR 
to ReCT using the recalculated dose. CBCTP is the DIR to daily CBCT using the planned dose. 
CBCTR is the DIR to daily CBCT using the recalculated dose. 
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Figure 5-4: The difference between predicted D95 and the prescribed dose for the PTV for using a) 
CBCTP and b) CBCTR methods compared to ReCTR (gold standard). Values are presented as the 
difference from the prescribed dose. ReCTR is the DIR to ReCT using the recalculated dose. CBCTP 
is the DIR to daily CBCT using the planned dose. CBCTR is the DIR to daily CBCT using the 
recalculated dose. 
To simulate a clinical decision-making situation, the results for both parotids and PTVs 
were combined to determine whether to adapt or not based on the dose predictions from 
CBCTP or CBCTR methods. Clinically, the plans for all 18 patients were adapted using a 
conservative approach based on anatomical changes alone but according to our dose 
analysis, only 7 were outside of tolerance leaving 11 potentially unnecessary adaptations. 
Using the CBCTP method there would have been only 4 unnecessary adaptations without 
missing any required adaptations. For CBCTR (with the recomputed dose) there would 
have been 2 unnecessary adaptations while also not missing any required adaptations. 
5.4 Discussion 
 In a standard workflow, the only dose distribution always available is the one 
calculated using the initial CT simulation for planning purposes. Theoretically, the dose 
gradients from the planned dose distribution indicate what dose differences may occur 
due to specific anatomical changes. Dose gradients are mainly defined by the original 
beam geometry relative to the planned iso-centre, which is not affected by deformation. 
Without extensive deformation, these gradients can be maintained and could predict dose 
change, when combined with a deformation field. However, with large volume or density 
reductions within the beams path significant changes to the dose distribution can result, 
93 
 
 
which could lead to missed adaptations, if no dose calculation is performed. But very 
large volume/density changes are clearly visible by visual inspection on imaging and 
would be flagged and trigger adaptation by a therapist. 
The average relative dose differences RDj for each organ presented in table 1 show that 
for both parotids and spinal cord the RDj from the CBCTR method (which is a result of 
DIR error alone) is similar to the results from the ReCTP method, which is the error from 
using the plan instead of the recomputed dose. The CBCTP RDj includes both sources of 
error but is less than the sum of errors in ReCTP and CBCTR methods.  
It has been shown that DIR error is specific to the algorithm used [27, 28] and image 
quality [22]. In this study, only one commercial algorithm was used to evaluate the utility 
of applying DIR to CBCT studies using an unmodified commercial product. More 
accurate dose estimations could be performed if registration error was known and 
accounted for as demonstrated in our previous work [29]. Typical plan adaptation 
strategies revolve around re-planning on the CBCT study using DIR to propagate 
contours and evaluate dose [30-32]. Two publications by Veiga et al. have evaluated the 
process of using DIR to CBCT studies for determining daily dose [23] and accumulated 
dose with different DIR algorithms [28], but in both cases dose computations are needed 
for each fraction. In this study, DIR of the daily CBCT study is proposed to evaluate 
anatomical changes without a re-scan of the patient or dose calculation using a 
commercial DIR algorithm. 
Practically speaking, DIR procedures can help physicians to decide when to adapt their 
radiation treatment plans. From the results presented in figures 3 and 4, the clinical 
decision to re-plan all 18 of these cases was not necessary, with 11 of the original patient 
plans still within clinical tolerances. Clinical decisions of plan adaptation were made 
before the re-scan using personal experience, which explains the discrepancy in 
adaptation rates between our GS and what was decided clinically. Our results have shown 
that both methods using daily CBCT studies (CBCTR and CBCTP) yielded very 
conservative results and missed no required adaptations. If the simplest prediction method 
(CBCTP) was used, only four patients would have been unnecessarily re-scanned and 
adapted. This demonstrates that using the DIR to the CBCT of the day without a dose 
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calculation in CBCTP method can determine when to adapt a treatment plan better than 
what was done clinically avoiding a number of unnecessary CT simulations and re-
planning efforts. Performing an additional dose calculation in CBCTR caught two 
additional unnecessary plan adaptations at the cost of additional computation time, while 
without a dose computation the procedure can be completed within one minute allowing 
for an efficient “adapt or not” decision online.  
5.5 Conclusion 
Improvements in IGRT and conformal radiation delivery have made adaptive radiation 
therapy a reality, but steps need to be taken to ensure its efficiency. Practical 
implementation requires an efficient method of daily evaluation and decision-making to 
determine when plan adaptation is truly necessary. The method of dose evaluation using 
on-board CBCT imaging alone is limited by the necessity for dose calculation, contouring 
and image registration. We have shown that the daily CBCT image mapped back to the 
planning CT without a dose calculation can provide sufficient information for the 
important decision of when to re-plan. The goal is to prevent the use of unnecessary 
additional CT simulations and dose computations with a quick online evaluation. Further 
research needs to be performed with more patients and other treatment sites including 
abdomen and thorax and for treatment techniques that will produce a different landscape 
of dose gradients. 
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Chapter 6 
 
6 Conclusion and future work 
6.1 Summary of findings 
This thesis has demonstrated (1) the significance of using patient data to guide physician 
decision making in radiation therapy, (2) the importance of including registration 
uncertainty, when applying DIR for dose accumulation, and (3) the need for outcome-
driven decision making schematically presented in Figure 1-7. In this chapter, the major 
findings of the four studies comprising this thesis and future work are summarized. 
6.1.1  Data-driven decision making in radiation therapy 
In the past, treatment decisions in radiation therapy, including dose prescriptions, have 
been made based on the physician’s experience including findings from clinical trials. 
With rapidly evolving technology and development of new treatment techniques, clinical 
trials cannot keep pace and are only attempted when large payoffs are expected. 
Unfortunately, current clinical trials cannot effectively optimize treatment prescription 
and delivery parameters for specific disease pathologies and patient characteristics. To fill 
this void and provide truly personalized medicine, real-time data-driven decision making 
is required, utilizing the large quantities of data available in this era of “Big data” [1]. 
Data-driven decision making requires large amounts of patient data to construct models 
predicting patient outcomes, including survival, disease control, and toxicity based on 
patient characteristics and available treatment options. Chapter 2 tackled this problem for 
patients suffering from hepatocellular carcinoma and metastatic liver cancer to predict 
overall survival and determine the candidacy for curative vs palliative treatment. The 
results of chapter 2 were two nomograms predicting overall survival for both patient 
groups, including the patient’s disease burden and liver function. Nomograms act as 
predictive models to guide a physician’s decision on how to best treat based on the 
patient’s pre-treatment information providing the link between patient data and treatment 
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decisions as shown in Figure 1-7. Chapter 2 demonstrated that using routinely collected 
patient data can help guide physicians with treatment decisions, and highlight new areas 
of research, that will improve patient care. For example, the prescribed radiation dose was 
not found to be a significant variable predicting overall survival with a p-value of 0.1 for 
the HCC model. Prescribed radiation dose only describes what was planned, not 
necessarily how the radiation was actually delivered. It can be speculated that using the 
actual delivered dose (acquired through DIR based accumulated dose) should improve the 
models of survival, which led to the work with DIR in chapters 3 and 4. With improved 
predictive models patients can receive treatments personalized for their unique biology. 
Aside from using patient data for pre-treatment decision making, it can also improve mid-
treatment decision making as to when to adapt a treatment plan. Currently, all mid-
treatment decisions are made based on the visual inspection of alignment devices (i.e. 
masks) or daily imaging (i.e. CBCT or 2D kilovoltage) by physicians. The method 
presented in Chapter 5 is not replacing clinical decisions but providing physicians with 
the dosimetric changes automatically and reliably in less than one minute before every 
treatment fraction. Additionally, the results of the study in chapter 5 demonstrated that the 
decision for plan adaptation could be made without the need for manual contours or a 
dose calculation. Typically, accurate dose analysis would benefit from a new dose 
calculation on the modified anatomy, but the results from chapter 5 demonstrate that in 
order to predict significant changes to a dose distribution, it is not always required. The 
conclusion from chapter 5 demonstrated that applying data-driven decision making can 
provide physicians with the daily dosimetric changes and make adaptive radiation therapy 
more reliable and cost-effective by initiating a re-planning procedure only when 
necessary.  
6.1.2 Including registration uncertainty of DIR for dose accumulation 
Deformable image registration is becoming a common tool in radiation therapy allowing 
for the propagation of contours between different image sets and the accumulation of 
dose between sets of images. Unfortunately, DIR inherently contains variable levels of 
accuracy creating significant uncertainty in any results it produces. Originally only rigid 
registration (including translations and rotations) was used in radiation therapy for 
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alignment of treatment images and target delineation, and any error could be visualized 
and quantified as a single value. DIR is defined by thousands of 3D deformation vectors, 
each having its own associated error vector. When DIR is used in conjunction with 
another 3D quantity such as absorbed dose the effect of registration error is magnified. 
For DIR to be effectively used in radiation therapy, the routine evaluation of DIR error 
and its impact on cumulative dose is required. 
In chapter 3, a new novel method for the evaluation of DIR was presented using an auto-
landmarking method based on the scale invariant feature transform (SIFT). Landmarking 
methods find corresponding points in a pair of images and tests how well the DIR can 
match the same landmark points. Previously landmark pairs could only be located 
manually requiring significant human resources, reserving their use to algorithm 
benchmarking [2, 3] and research [4]. The method presented in chapter 3 created 
landmarks comparable to high-quality gold standard landmarks and reproduced local 
deformation values with an ICC value of 0.96. The primary limitation of automatic 
landmarks is the number and distribution which are heavily influenced by the type and 
quality of images used. For frequent routine evaluation, only a small number of 
landmarks representative of the anatomy and the dose distribution are required, compared 
to the large number of landmarks required for DIR algorithm benchmarking. With the 
method from chapter 3, the routine evaluation of DIR is possible enabling the accurate 
daily use of DIR in the clinic. Accurate DIR with IGRT is the best method to determine 
the cumulative dose distribution providing the link between what was planned and 
delivered as shown in Figure 1-7.  
One of the primary uses of DIR in radiation therapy is the accumulation of dose 
throughout a multi-fraction treatment using the CBCT studies provided by IGRT. Dose 
accumulation uses the DVF to map the dose from individual fractions back to the original 
treatment plan to determine the actual delivered dose. The accuracy of a dose 
accumulation is determined by the accuracy of each vector within the deformation field 
multiplied by the local dose gradient. Previously, the only option was to apply the best 
available DIR algorithm, with no account of the registration error. The dose accumulation 
error cannot be easily included because of the distribution of registration errors 
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throughout an image volume. If the registration error is high in regions with a large dose 
gradient, there will be a large dose accumulation error and a homogeneous dose region 
with a low dose gradient will have a low dose accumulation error. Chapter 4 presented a 
method of incorporating the distribution of registration error into the dose accumulation 
process to provide the range of accumulated doses. The method in chapter 4 was also 
shown to work with DIR uncertainty values calculated from statistical, or consistency 
metrics. Currently, the best option is to cumulate radiation dose assuming the registration 
is 100% accurate, but with the method presented in chapter 4, a realistic range of 
cumulative dose values can be obtained. With a realistic range of delivered dose values, 
an accurate account of radiation treatment can be obtained and fed into an outcome-
driven decision-making process as shown in Figure 1-7. With the real delivered dose 
stronger predictive models can be produced to guide physicians in their treatment 
decision for each new patient.  
6.2 Future work 
6.2.1 Automatic DIR evaluation of different disease sites. 
In chapter 3 an auto-landmarking algorithm was applied and evaluated for lung CT 
studies, demonstrating its ability to quickly evaluate DIR. To increase the viability of 
auto-landmarking methods, tests with other treatment sites and imaging modalities should 
be performed. Important disease sites exhibiting large amounts of deformation during 
radiation therapy include head and neck, breast, and cancers within the abdomen and 
pelvis (i.e. prostate). This land-marking method should also be tested on different 
imaging modalities including CBCT and MRI, investigating the method’s performance 
between like (i.e. CBCT-CBCT) and different modalities (i.e. MRI-CBCT). Effective 
testing of a landmarking method requires manual gold standard landmark sets similar to 
the gold standard landmarks used in chapter 3. With gold standard landmarks for each 
treatment site and imaging modality, the presented algorithm can be tested and optimized 
with the goal of being introduced for routine DIR evaluation. It is also important to test 
other land-marking algorithms and compare them to those generated by SIFT. For 
example, other land-marking algorithms include an edge based region detector [5] or 
Speeded-up robust feature detection (SURF) [6]. There is also potential to improve upon 
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the current SIFT implementation to improve landmark yield and quality as shown in 
Yang et al. [7].  With the routine evaluation of DIR, it can be used freely to assess daily 
anatomy or determine the cumulative dose distribution and be correlated with outcomes. 
6.2.2 Clinical application of DIR with uncertainty. 
DIR continues to grow in popularity in radiation therapy, being included in almost every 
treatment planning system and medical imaging software. From the methodologies and 
data in chapters 3 and 4, the accuracies of DIR algorithms vary significantly and they 
need to be routinely evaluated, and the inaccuracies incorporated into any resulting 
analysis. To achieve this, the auto-landmarking methods presented in this thesis can be 
included in any DIR package, and the resulting error on each vector can be used to 
interpret the final error in the cumulative dose analysis. The final result of any DIR 
should provide error bars on the cumulative dose distribution to better understand what 
was actually delivered and how it correlates with patient outcomes.  
6.2.3 Modelling treatment outcomes with more realistic delivered dose. 
Traditionally, effects of radiation therapy have been modelled based on planned dose 
parameters, for example, the dose to 95% of the target volume. Historically, only 
important dose parameters from a radiation treatment plan were recorded and linked 
radiation effects and treatment. With newer technologies and techniques, detailed data are 
available describing the specific spatial distribution of radiation dose, relative to different 
tissue types and organs. The spatial distribution of the delivered radiation dose could then 
help to further explain the effects of the radiation dose, including radiation-induced 
toxicity and tumour control. The next step is to include daily image guidance and DIR to 
know the actual delivered dose to patients and provide the most detailed account of a 
radiation treatment. 
Current forms of DIR are not accurate enough to be used for dose accumulation without 
accounting for the registration uncertainty. In this thesis, two methods have been 
presented to allow for a more accurate use of DIR through the incorporation of 
registration uncertainty. When DIR is applied for dose accumulation it can be evaluated 
using the auto-landmarking method presented in chapter 3 and determine the spatial 
distribution of registration error. With the known spatial distribution of registration error, 
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the dose accumulation error can be calculated using the method from chapter 4 on each 
individual treatment fraction. Information about the dose accumulation error can 
determine which patients have an accurate account of their delivered radiation treatment 
and can be correlated with outcomes. Although dose uncertainties are vital for developing 
tools for a physician’s decision making, clinical significance comes down to absolute 
cumulative dose to regions of interest for both TCP and NTCP assessment. Further 
studies can produce predictive models between the “real” delivered dose and patient 
outcomes to be implemented in outcome-driven decision making as shown in Figure 1-7. 
The ultimate goal is to use the record of real radiation dose to further improve predictive 
models and work towards personalized medicine using the already available patient data. 
The goal of this thesis is to present methods for the incorporation of outcome-driven 
decision making in radiation therapy and facilitate personalized treatments for patients 
based on their own specific biology. It is hoped that this work will provide the roadmap to 
implement outcome-driven decision making in radiation therapy clinics and utilize the 
large amount of available clinical data to significantly improve patient care. 
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Appendix A: Permission to reproduce published material 
A.1 Permission to reproduce content for Figure 1-3a 
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A.2 Permission to reproduce content for Figure 1-3b (same license 
agreement as A.1) 
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A.3 Permission to reproduce the content of chapter 2 from Future 
Oncology 
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A.4 Permission to reproduce the content of chapter 3 and 4 from 
Physics in Medicine and Biology 
From the publisher's website https://publishingsupport.iopscience.iop.org/permissions-
faqs/ 
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number of rights. These include the right to include the Final Published Version of the 
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online use, a link to the Version of Record. IOP’s permission will be required for 
commercial use of an article published as part of your thesis. IOP does not allow 
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Appendix B: Description of clinical parameters and tools from 
chapter 2 
B.1 Important clinical measures for liver cancer patients 
In the diagnosis and treatment of liver cancer there are a number of important clinical 
measures that are used to describe a patients overall liver function. Bilirubin is a protein 
found in the blood and is created in the liver with high levels being indicative of liver 
disease. Serum albumin is the most abundant protein found in human blood, and low 
levels of serum albumin are also indicative of liver disease. Ascites describes a patient 
retaining water within their liver and another indicator of liver disease. Child Pugh score 
is a common measure of a patients liver function ranging from A to C indicating good to 
poor liver function respectively. Child Pugh score is calculated from the combination of 
different clinical factors including bilirubin, serum albumin and ascites. 
B.2 Interpreting Cox proportional hazard model results. 
The Cox proportional hazard model is used to find the association between specific 
variables (either continuous or binary) and overall survival. The Cox proportional hazard 
model is a linear regression solving for equation 1, where λ(t) is the hazard rate, λo(t) is 
the baseline hazard function, X1-Xn are the different variables and β1-βn are the model 
parameters determined for each variable.  
ߣ(ݐ) = ߣ଴(ݐ)exp (ߚଵ ଵܺ + ⋯+ ߚ௡ܺ௡)       (1) 
Hazard rate describes the risk of death and a higher hazard rate describes lower survival. 
The primary results of a Cox proportional hazard model are the β values, hazard ratio 
(with 95% confidence interval) and p-values. β values describe the relationship each 
variable has on survival for example a positive β value indicates  a higher hazard rate and 
lower survival. Hazard ratios also describe the effect each variable has on overall 
survival, hazard ratio > 1 describes poor survival and hazard ratio < 1 describes better 
survival. A p-value measures the significance of the variable on overall survival, with a p-
value < 0.05 indicating a significant result.  
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Cox proportional hazard model results are presented for both univariate and multivariate 
analysis. Univariate analysis describes the individual effect of each variable on survival. 
Multivariate analysis describes the effect each variable has on survival when combined 
with other significant variables chosen for the final model.  
B.3 Applying a nomogram 
Clinical nomograms visualize predictive models created using a cox proportional hazard 
model for application in the clinic. A diagram describing the process of a nomogram is 
presented in figure B-1, describing how the score is summed and converted to a one year 
and six month survival probability. 
 
Figure B-1: Diagram describing the use of a clinical nomogram, using clinical variables to determine 
the probability of one year and six month survival. 
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Appendix C: Description of the Scale Invariant Feature 
Transform (SIFT) 
C.1 Scale invariance 
The Scale Invariant Feature Transform (SIFT) was engineered to match points between 
two images regardless of relative scale (scale invariant). If two images are taken with the 
same imaging system, they can be compared and matched based on the voxel intensities 
directly .When the imaging systems are different direct voxel comparison is no-longer 
valid because of scaling differences. In-order to compare two images together regardless 
of scale the difference of Gaussian images is selected as presented in Lowe et al [1]. 
The difference of Gaussian images is computed by convolving an image with the 
Gaussian filter with a defined scaling σ (equation 1) and subtracting it from an image 
convolved with a Gaussian filter with different scaling kσ (equation 2).  
ܮ(ݔ, ݕ, ݖ,ߪ) = ଵ(√ଶగఙ)మ ݁ି(௫మା௬మା௭మ)/ଶఙమ ∗ ܫ(ݔ, ݕ, ݖ)     (1) 
ܦ(ݔ, ݕ, ݖ, ݇ߪ) = ܮ(ݔ, ݕ, ݖ, ݇ߪ) − ܮ(ݔ,ݕ, ݖ,ߪ)     (2) 
The result is an image describing the gradients within the image, regardless of scale. Also 
the Laplacian of the Gaussian can be approximate from the difference of Gaussian 
images, using a modified heat equation using σ in place of t (shown in equation 3).  
ߪ∇ଶܩ = డீ
డఙ
≈
ீ(௫,௬,௭,௞ఙ)ିீ(௫,௬,௭,ఙ)
௞ఙିఙ
       (3) 
The result is an approximate Laplacian of the Gaussian at every point in the image 
volume and at different scaling values construct a 4D (x,y,z,σ) matrix used to locate 
unique points. 
C.2 Finding unique points 
Once the 4D matrix (x,y,z,σ) of the Laplacian of the Gaussian is constructed the next step 
is to find local maximum and minimum values. This is performed by finding the local 
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maximum and minimum voxels when compared to all the nearest neighbors across all 4 
dimensions (80 neighboring points).  
C.3 Removal of edge points 
With all the unique points located the next step is to remove points that are located on an 
edge because they can have strong difference of Gaussians while not actually being 
unique. This is performed by looking at the magnitude of the primary and secondary 
eigen-vectors (direction with the highest rate of change). If the magnitude of the primary 
eigen-vector is Hmax times greater than the secondary eigenvector it is located on an edge 
and excluded as a unique point. The parameter Hmax is tuned for the specific imaging 
system being used. 
C.4 Point localization 
All landmark locations are limited by the resolution of the image volume being used, but 
perhaps the true unique point could lie in between 3D voxels. To interpolate between 
voxels and localize the approximate maximum or minimum a 2nd order Taylor expansion 
is used (shown in equation 4) with x = (x,y,z,σ). To locate the maximum and minimum the 
derivative of the Taylor series is set to zero and solved for the localized point v (shown in 
equation 5). 
ܦ(࢞) = ܦ +  డ஽
డ࢞
்
࢞ + 0.5்࢞ డమ஽
డ࢞మ
࢞       (4) 
࢜ = − డమ஽
డ࢞మ
ିଵ డ஽
డ࢞
         (5) 
Once the point is localized in 4D, the new value is measured from the Taylor series and if 
it is below rthresh it will be excluded. The rthresh parameter is selected to remove points with 
low contrast.  
C.5 Point descriptors and matching 
With all unique points located in an image study the next step is to create descriptors 
describing each point. The first step is to subdivide the surrounding voxels into 4x4x4 sub 
volumes each containing 4x4x4 voxels, totaling 16x16x16 voxels centered on the unique 
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point being described. For each voxel the gradient magnitude and direction (both 
azimuthal and elevation directions) is computed. Now each sub volume includes the 
magnitude and direction for 4x4x4 voxels and the gradient magnitude is binned into an 8 
by 4 matrix based on their azimuthal (8 directions between 0 and 360) and elevation (4 
directions between 0 and 180) directions respectively. To have more distinct feature 
matching the gradient magnitudes can be scaled based on their distance from the center of 
the sub volume. The final descriptor is a 4x4x4x8x4 matrix describing each unique point. 
With each unique point in two image volumes having a descriptor the next step is to 
match like points between each image. The fastest matching method is to convert each 
descriptor (4x4x4x8x4) into a 2,048 dimensional vector and finding the Euclidian 
distance between every possible unique point pair. For example for one unique point you 
would calculate the Euclidian distance between the 2,048 dimensional vectors from all 
points in the other image and find the point with the smallest “Euclidian distance”. If the 
next closest point has a Euclidian distance 1.66 times greater than they are matched 
together. The distance to the next most similar point (1.66) is chosen to find the balance 
between the number and quality of landmarks, a smaller multiplier would yield more 
points with potentially less similarity. The end results are landmarked points between two 
3D volumes.  
C.6 Optimization 
When implementing a SIFT algorithm there is a balance between the number and quality 
of matched points. This balance is changed by changing the kσ, Hmax, rthresh and distance 
to next most similar point. Each of these parameters affects how many unique points are 
considered or the matching criteria and they need to be optimized for the specific type of 
images (etc. CT or MRI) or what is being imaged (etc. thorax vs brain).  
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